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Abbreviations: 
 
 
 
EDC   Pittsburgh Epidemiology of Diabetes Complications Study 
DERI   Diabetes Epidemiology Research International Study 
T1D   Type 1 Diabetes 
CAD   Coronary Artery Disease 
MI   Myocardial Infarction 
ECG   Electrocardiogram 
RV   Revascularization Therapy 
PTCA   Percutaneous Transluminary Coronary Angioplasty 
CABG   Coronary Artery Bypass Grafting 
ON   Overt Nephropathy 
MA   Microalbuminuria 
AER   Albumin Excretion Rate 
ESRD   End-stage Renal Disease 
RRT   Renal Replacement Therapy 
PAI-1   Plasminogen Activator Inhibitor-1 
tPA-PAI-1  Tissue Plasminogen Activator-PAI-1 Complex 
HbA1   Hemoglobin A1 
HbA1c   Hemoglobin A1c 
SMR   Standardized Mortality Ratio 
CI (95%)  Confidence Intervals (95%) 
SD   Standard Deviation 
OR   Odds Ratio 
HR   Hazard Ratio 
RR   Relative Risk 
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Abstract 
 
 
Despite the major increase in life expectancy and the development of new technology 
in diabetes health care, individuals who develop Type 1 diabetes (T1D) remain at 
substantially greater risk of early mortality. The acute and chronic complications of diabetes 
might markedly contribute to this. There are only few studies that have accurately quantified 
the mortality risk associated to complications of T1D. Little is known about the underlying 
cause of this mortality excess, gender and national/ethnic differences and the temporal 
changes in mortality by different T1D complications. Once complication developed, survival 
pattern after preventive strategies becomes important in order to find better approaches to 
prolong lifetime of those living with T1D. 
The current PhD thesis is designed to evaluate the cause specific mortality pattern of T1D 
through the presence of major diabetes complications (coronary artery disease and renal 
disease), and to examine demographic factors and causes influencing survival, also after their 
invasive treatment.  
Persons with T1D in the Pittsburgh Metropolitan Area, in Allegheny County, Pennsylvania, 
USA, in Havana, Cuba and in Pecs, Hungary were identified primarily from population based 
incidence registries of Type 1 diabetics. Participants diagnosed with T1D between 1965 and 
1979, at age <17 years were enrolled into the mortality study. The underlying and secondary 
causes of death were determined by a Mortality Committee using standardized survey and 
protocol. Complication data were collected from the Pittsburgh Epidemiology of Diabetes 
Complication (EDC) Study, a large prospective cohort of childhood-onset (<17 yrs) T1D 
diagnosed 1950-1979, and from the albuminuria screening program of T1D children (<18 
yrs), a hospital-based dataset at the University of Pecs, Departement of Pediatrics. 
African Americans (particularly females) and Hispanics had a greatly increased risk of death 
compared to Caucasians which was attributable to acute complications in African Americans 
while to renal disease in the case of Hispanics. Males were more likely to die from non-
diabetes related causes than females. There was a temporal decline in the 20-year mortality 
rates in both racial groups across the cohorts diagnosed in 1965-69, 1970-74 and 1975-79. 
The 5-year prevalence of microalbuminuria was found to be significantly lower among 
patients with early childhood (0-4 years) onset T1D compared to those in higher age groups 
(5-9, 10-17 yrs) by diabetes onset. The incidence of overt nephropathy and end-stage renal 
disease (ESRD) has declined, probably reflecting the better glycemic and blood pressure 
control available since the early 1980s. Revascularization in coronary artery disease and renal 
replacement therapy in ESRD can prolong survival after major complications developed. 
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Magyar nyelvű összefoglalás 
 
 
Az utóbbi években növekvő incidenciát mutató gyermekkorban diagnosztizált 1-es 
típusú diabétesz egyre elterjedtebb globális megbetegedés, ami a kora-felnőttkori halálozások 
nagy részéért felelőssé tehető. A diabétesz akut és krónikus (mikro- illetve makrovaszkuláris) 
szövődményei jelentősen hozzájárulhatnak a rossz halálozási mutatókhoz. Kevés adatot 
találunk viszont a magas mortalitási mutatókhoz vezető elsődleges okokról az esetleges nemi 
illetve származás (rassz) beli különbségekről valamint az utóbbi évtizedek tendenciáiról. A 
szövődmények kialakulását követően az egyes invazív eljárásokat követő túlélési adatok 
elemzése segíthet a megfelelő preventív stratégiák kiválasztásában. 
Jelen PhD dolgozat megírása során célul tűztem ki az 1-es típusú diabétesz egyes 
szövődményeihez (kiemelten kezelve a koszorúér betegséget illetve a nefropátiát) köthető 
halálozási adatok elemzését valamint egyes demográfiai és egyéb tényezők túlélésben 
(invazív kezelést követően is) játszott szerepének vizsgálatát.  
A vizsgálatban Pittsburgh város és vonzáskörzete, Allegheny-megye (Pennsylvania, USA), 
Havanna (Kuba) illetve Pécs 1-es típusú diabéteszes betegeinek adatát elemeztük. A 
mortalitás vizsgálatához 1965 és 1979 között, gyermekkorban (<17 év) diagnosztizált és 
inzulinra állitott betegek követési adatait használtuk fel. A halál közvetlen okát, az ahhoz 
vezető tényzőket valamint a diabéteszes szövődmények szerepét a rendelkezésre álló orvosi 
dokumentáció alapján, az e célra kidolgozott standardizált protokoll szerint egy szakértői 
bizottság állapította meg a végső feldolgozás számára. A szövődmények elemzéséhez a 
Pittsburgh Epidemiology of Diabetes Complications (EDC) vizsgálat (diagnózis: 1950-1979, 
<17 év) valamint a Pécsi Tudományegyetem Gyermekklinikáján indított albuminuria szűrés 
(diagnózis <18 év) adatait használtuk fel. 
Az afro-amerikaiak (különösen a nők) valamint a hispán származásúak (Kuba) 
összmortalitása az amerikai fehér betegek adataival összehasonlítva jóval magasabb értéket 
mutatott. Ezen különbségek a feketék esetében főként a akut szövődmények, míg a kubaiak 
esetében a veseszövődmények magas előfordulásának tulajdoníthatók. A nemi 
összehasonlításban a férfiak között a cukorbetegséghez nem köthető halálokok (pl. 
öngyilkosság, baleset, rákos megbetegedés) előfordulása magasabb volt. Csökkenő tendenciát 
figyeltünk meg a 20 éves halálozási adatokban a diabétesz diagnózisának időpontja (1965-69, 
1970-74, 1975-79) szerint. A szövődmények elemzésekor a kisgyermekkorban (0-4 év) 
diagnosztizált cukorbetegek csoportjában a microalbuminuria 5 éves prevalenciája 
szignifikánsan alacsonyabb volt a későbbi életkorban (5-9, 10-17 év) diagnosztizáltak 
prevalencia értékeihez képest. A manifeszt nefropátia és a végstádiumú vesebetegség 
incidenciája az utóbbi évtizedekben látványosan csökkent, feltehetően az 1980-as évektől 
megfigyelhető folyamatosan javuló glikémiás és vérnyomás kontrollnak köszönhetően. A 
koszorúérbetegséget követő revaszkularizáció valamint a súlyos vesebetegség esetében 
használt vesepótló kezelések az adatok alapján megteremthetik a hosszabb túlélés lehetőségét 
a szövődményektől szenvedő 1-es típusú diabéteszes betegek számára. 
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1. Introduction 
 
Type 1 diabetes (T1D) is one of the most common serious chronic diseases of childhood. The 
majority of cases are classified as autoimmune diabetes, which usually is due to destruction of 
the B-cells of the Langerhans islets, however, non-autoimmune forms (e.g. maturity-onset 
diabetes of youth – MODY) have been recognized more often in the recent years. 
 
Epidemiology of Type 1 diabetes 
Among children, Type 1 diabetes is usually the most prevalent form of the disease. This 
disorder occurs with an annual incidence of 17 to 18 cases per 100,000 persons younger than 
19 years. The prevalence rate is increasing because the incidence is rising and mortality rates 
are decreasing. One of the more intriguing aspects of the studies in the field of epidemiology 
of Type 1 diabetes is the remarkable variation in prevalence and incidence in various parts of 
the world. Incidence figures are lowest in Asia; Japan, Korea, and China report approximately 
one case per 100,000 people each year. Rates are highest in the Scandinavian countries, 
especially Finland, and in Sardinia, with incidence rates approaching 40 cases per 100,000 
children and adolescents per year. The explanation for these geographic differences is still 
unclear. Although the frequency of genetic susceptibility haplotypes probably plays a major 
role among the different races, other populations have very similar gene frequencies. Thus, 
geographic variations and the rising incidence of T1D around the world point to the role of 
yet-to-be-determined environmental factors in precipitating insulin deficiency. 
Approximately 5-15% of patients with known diabetes have Type 1 diabetes. A large 
proportion of these patients (probably >60%), acquire the disease before the age of 20, 
recognition is increasing that the disease may present in adulthood. In childhood, the mean 
age of onset is ~8 years. A peak is seen in adolescence, which occurs somewhat earlier in girls 
than in boys. A rise in incidence has been reported among children younger than 5 years. No 
significant difference is seen in sex distribution of diabetes during childhood. 
 
Future for a child with Type 1 diabetes 
In the last one and a half decades, important research advances have been made in patient 
management. One of the most significant in terms of convenience for the patient with diabetes, 
particularly the school-age child and adolescent, is the availability of modern analogue insulin 
short-acting and long-acting insulins, the new easy-to-use insulin delivery devices, the smaller 
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glucose-monitoring meters and continuous glucose sensor systems and, last but not least, the 
convenient subcutaneous insulin infusion pumps are becoming widely available. 
Unfortunately, despite the development of new technology in diabetes health care, individuals 
who develop T1D remain at substantially greater risk of early mortality. Children with T1D 
appear to be still much more likely to die than comparably aged individuals in the general 
population. The complications of diabetes markedly contribute to this. 
The Diabetes Control and Complication Trial (DCCT) results unequivocally documented that 
sustained metabolic improvement in diabetes control is associated with highly significant 
reductions in the frequency, severity, and rate of progression of the serious microvascular 
complications. But there are only few large, consistent studies that have accurately quantified 
the mortality risk associated to acute and chronic complications of Type 1 diabetes. Little is 
known about the underlying causes of this mortality excess and the temporal changes in 
mortality by different T1D complications. 
Epidemiological research is expected reveal more the causes behind the excess mortality and 
worse survival and might explain the interrelationships between demographic data, early 
markers, risk factors, complications and mortality patterns. 
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2. Review of the literature 
 
2.1. Mortality studies of patients with Type 1 diabetes 
 
Before the discovery of insulin by Banting and Best in 1922, the onset of childhood diabetes 
represented almost certain death, the life expectancy of a child with Type 1 diabetes was in 
general not more then two years from diagnosis. After insulin has entered into clinical use, 
life expectancy for newly diagnosed patients with diabetes has dramatically increased (Borch-
Johnsen K 1989). However, even as insulin became available widely, it was experienced that 
childhood diabetes was still associated with markedly excessive premature mortality (Borch-
Johnsen K 1989). Several decades then elapsed before it was documented in the literature that, 
even with insulin treatment, diabetic patients are still at a significantly increased risk of dying, 
not only of acute diabetes-related complications but also of late complications such as 
diabetic nephropathy and macrovascular disease (Joslin EP 1950, White P 1956, Entmacher 
PS 1964).  
 
2.1.1. Types of mortality studies 
 
Diabetes mortality has been studied by making use of routinely collected vital statistic data, 
sometimes including more detailed analyses of death certificate data and by conducting 
follow-up studies involving diabetic patients. The majority of published follow-up studies 
have been hospital-based (e.g. Entmacher PS 1964, Dorman JS 1984, Borch-Johnsen K 1985) 
and some have presented the outcome in diabetics who has applied for life insurance (Pollack 
AA 1967, Goodkin G 1975). However, still only a few studies have been population-based, 
following all diabetes patients diagnosed in a certain region over a specified period of time 
(Joner G 1991) or all prevalent patients identified in a defined population (Moss SE 1991). 
Ideally, in a prognostic study patients should be followed from the time of diagnosis in order 
to avoid selection of a survivor population (Kaplan MH 1973). 
Vital statistics and death certificates are a readily available source of information on diabetes 
mortality. Death certificates form the basis of information for vital statistic, however, the 
results of this type of studies are highly influenced by the certification process. Variation in 
instructions on filling in death certificates and differences in coding procedures can also 
influence the evaluation (Jougla E 1992). It is not unusual for there to be no mention at all of 
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diabetes on death certificates, although it is more common to mention diabetes if insulin 
treatment was given. The majority of death for which diabetes is mentioned on the death 
certificate are coded under other causes of death (Fuller JH 1983) which further reduces the 
value of routine mortality statistics based on a single underlying cause of death. 
The hospital-based studies often come from centers with a special interest in diabetes 
research and treatment. The best-known centers where large-scale follow-up studies on Type 
1 diabetes patients have been conducted are the Joslin Clinic in Boston, USA, the Steno 
Memorial Hospital in Denmark and the Children’s Hospital in Pittsburgh, USA. The major 
potential reasons for selection bias in hospital-based study populations are: 1. referral of 
patients with complications or poor metabolic control; 2. socio-economically biased referral 
influenced by income or availability of (private) health insurance and; 3. selective referral of 
patients owning to the special fields of interest at a centre. 
A population-based mortality follow-up study requires identification of all people with 
diabetes in a specified population. The study population of the Children’s Hospital in 
Pittsburgh has been extended to cover all patients with Type 1 diabetes diagnosed in 
Allegheny County between 1965 and 1979 (LaPorte RE 1981) and now comprises one of the 
few large population-based mortality follow-up studies. The original study population of the 
Children’s Hospital was compared with the population-based register and the patients did not 
differ in basic characteristics. To avoid bias by selective referral, only patients admitted to the 
Hospital at the time of diagnosis or at latest within a year of diagnosis were included in the 
mortality follow-up studies (Dorman JS 1984).  
 
2.1.2. Mortality studies in the USA 
 
Several population- and hospital-based studies have been reported by researchers in the USA. 
The population studies concerning both types of diabetes in the Mayo Clinic, Rochester, 
Minnesota were relatively small and the number of patients with T1D diagnosed before the 
age of 30 was low (Johnson DD 1980).  
Results from the Joslin Clinic showed that 10-year survival of patients diagnosed as having 
diabetes in the 1930s was higher than 90% (Marks HH 1965). Publications from the same 
clinic indicated that the mortality risk for young diabetic patients was between 12 and 14 
times higher than that of the general population, and that there was a marked increase in 
mortality after 35 years of age (Marks HH 1965). The study was, however, potentially biased 
by an over-representation of individuals with diabetic complications (Deckert T -I 1978). 
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Furthermore, no attempt was made in the Joslin studies to determine the representativeness of 
the population. 
Sultz et al. described the mortality experience of 289 T1D patients from Erie County, New 
York, who were diagnosed between 1946 and 1961 (Sultz HA 1972). During the 15-year 
follow-up period, seven cases had died. The data indicated that 2% of the children in this 
cohort died during the first 10 years of diabetes. Although the sample size was very small, this 
study was the first published population-based mortality examination in the USA.  
More recently, a follow-up study from the Children’s Hospital of Pittsburgh reported that the 
mortality of subjects diagnosed between 1950 and 1981 was seven times higher than that of 
the general population as of 1982 (Dorman JS 1984). The study also showed that the 10-year 
mortality decreased from 4.1 to 1.4% during this period. However, these results do not 
necessarily represent the mortality of the total diabetic population, because the study was 
hospital-based. 
In a larger population-based cohort in Allegheny County, Pennsylvania, with a 19-year 
minimum and a 34-year maximum follow-up (duration) of diabetes, the mortality of patients 
with T1D was more than 5 times higher than that of the general population with an overall 
SMR of 519 (95% CI 440–672) (Nishimura R 2001). Mortality, especially after 15 years 
duration of diabetes declined during the study’s last 30 years. SMRs at 20-year duration of 
diabetes showed a decreasing tendency over the study period, indicating that in US improving 
prognosis of diabetic children was greater than that of the general population. The prognosis 
of African-Americans, however, was much worse than that of Caucasians after 25 years of 
diabetes, although the decline in mortality seemed to be similar in both Caucasians and 
African-Americans (Nishimura R 2001). 
 
2.1.3. Cross-county comparisons in Type 1 diabetes mortality 
 
International comparative studies offer an excellent method for identifying areas with high 
number of diabetic complication-related deaths; areas where preventive measures could be 
implemented. Type 1 diabetes still leads to a two- to tenfold excess risk of mortality in 
developed countries, whereas in developing countries, a large proportion of diabetic patients 
die within a few years of diagnosis (WHO 1990). 
The Diabetes Epidemiology Research International (DERI) group conducted an international 
study comparing the mortality (as of 1 January 1990) of patients diagnosed between 1965 and 
1979 in population-based registries from four countries: USA (Allegheny County, PA), 
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Finland, Japan and Israel. The mortality in Allegheny County was five times higher than that 
of the general population (DERI Study Group 1991, 1995). Despite the fact that the United 
States currently has one of the most technologically advanced and costly systems of diabetes 
care in the world, more than 50 percent of the Type 1 diabetes-associated deaths are estimated 
to be in excess compared to Finland. European reports of population-based studies from 
Norway (Joner G 1991) and the UK (Warner DP 1998, McNally PG 1995) suggest that the 
mortality of children with Type 1 diabetes was two to three times higher than that of the 
general population. The report from the UK also noted that the standardized mortality ratios 
(SMRs) decreased from 981 to 238 during the period 1940–1989 (McNally PG 1995). The 
DERI group has recently demonstrated a considerable variation across countries and the 
possible risk factors for the excess mortality in Japan and the United States in contrast to 
Israel and Finland (DERI Study group 1991, Patrick SL 1992). These geographic differences 
highlight countries and societies such as Japan and the USA where mortality is excessive and 
could be reduced. 
By employing frequency adjusted diabetes mortality statistics Matsushima et al. were able to 
extend the geographic comparisons for the four populations to 24 populations (Matsushima M 
1997). Mortality data for diabetes in the 0–24 year age group were obtained from World 
Health Organization (WHO) statistics. The mortality rates were adjusted for the frequency of 
occurrence of Type 1 diabetes by dividing the mortality rates by the Type 1 diabetes 
incidence rates which were obtained from the WHO DiaMond project. The results 
demonstrated an almost 10-fold variation in the risk of dying across countries, with young 
Japanese and Eastern Europeans having by far the highest mortality (Matsushima M 1997). 
The areas having the best outcome associated with Type 1 diabetes were Northern Europe, 
Central Europe, and Canada. As the Type 1 diabetes incidence rates were measured in the 
comparable way, they are considered reliable. The results from the DERI mortality study 
suggest that there is a high congruence across countries concerning mortality of T1D patients 
before 25 years of age with a similar proportion of patients being reported on death 
certificates. It is unlikely that a more than 10-fold difference in mortality risk could be 
attributed to differential completion of death certificates.  
The EURODIAB study examining mortality in Europe in the years after diagnosis but before 
the onset of cardiovascular and renal complications demonstrates that significant excess 
mortality persists in the years following the diagnosis of Type 1 diabetes in childhood 
(Patterson CC 2007). Most of the excess of deaths were directly attributable to diabetes, and 
in the majority of such deaths there was mention of diabetic ketoacidosis. Variation between 
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countries is evident in this excess mortality, but these results do not suggest that it can be 
explained by a country’s incidence rate or gross domestic product. There has been, however, a 
shortage of data on mortality in T1D in the Eastern European countries. 
Population-based data from two Eastern European countries, Estonia and Lithuania was 
examined by Podar et al. (Podar T 2000). Survival of the patients in the Estonian and 
Lithuanian cohorts was quite similar, as both countries were part of the former Soviet Union 
and subject to similar health care practices. When compared to the Finnish cohort, people in 
Finland had better survival than in the two Baltic countries which is hardly explainable by 
inequalities in access to health services between Finland and the Baltic states. Furthermore, 
mortality in the general populations of Esonia and Lithuania has been found to be much 
higher than that in the developed countries bordering the Baltic Sea (Wedel H 1992). 
Compared with the background population, the survival of childhood-onset Type 1 diabetic 
patients in the two Baltic states is also worse than it is in Sweden and Norway (Sartor G 1991, 
Joner G 1991), where the SMR is 2, and similar to that in a study from Japan (Nishimura R 
1996). The most frequent cause of death in these two Baltic countries was diabetic 
ketoacidosis, the main killer of the pre-insulin era which could be potentially prevented. The 
occurrence of violent death was also high, in this North-East-European region, particularly in 
Finland. 
Mortality data for cohorts of people with T1D from developing countries are lacking. This 
might be due to the relatively low prevalence of the disease and the inevitable problems in 
identification of subjects and ascertainment of death (McLarty DG 1991, Lester FT 1992). 
Data from the African continent showed an unfavorable position for the African population 
when it comes to diabetes-associated mortality. A study from Tanzania, including subjects 
with both types of diabetes, has shown a 60% survival rate at 5 years of diabetes duration 
(McLarty DG 1991). This effect is probably caused by poor access to health care, missed 
diagnosis, and the unavailability of insulin in most African countries (McLarty DG 1991, 
Lester FT 1992). In a report from Cuba on a large cohort of people with Type 1 diabetes with 
prolonged follow-up, diabetic individuals with onset before 15 years of age had a much better 
prognosis compared to other developing countries. However, the survival of Cuban diabetics 
was inferior compared with cohorts from developed countries. This was particularly true 
when diabetes duration was more than 10 years. After 20 years of disease duration, the Cuban 
cohort had a cumulative survival rate of 84%, considerably less than the 97%, the 95%, and 
the 94% reported cumulative survival rate at the same years of follow-up for the Finnish, 
Israeli, and Allegheny County cohorts, respectively (DERI Study Group 1991).
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2.2. Coronary artery disease in Type 1 diabetes 
 
A high occurrence of, and mortality from coronary artery disease (CAD) in Type 1 diabetes 
has been documented since the late 1970s (Deckert T -II 1978, Christlieb AR 1981). A 1984 
registry reported a 10-fold or greater CAD mortality compared with that expected from USA 
national data (Dorman JS 1984). This very high relative risk, partly reflecting the extremely 
low CAD death rate in the general young adult population, was subsequently confirmed by 
Joslin investigators (Krolewski AS Am J Cardiol 1987), who reported that those with Type 1 
diabetes by 55 years of age experienced a sixfold greater cumulative CAD mortality 
compared with the rate expected using Framingham Study data. The Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR) also reported a standardized 
mortality ratio (SMR) from ischemic heart disease of 9.1 (for men) and 13.5 (for women) for 
those with a diabetes diagnosis before 30 years of age (Moss SE 1991). 
Many different studies have examined the early stages of CAD with the purpose to find some 
easily detectable parameter to prevent cardiovascular events. The excess coronary artery 
calcification (CAC) in Type 1 diabetes seen in studies from Denver (Dabelea D 2003) and 
London (Colhoun HM 2000), compared with general nondiabetic control populations, provide 
further support to the thesis of accelerated atherosclerosis in the coronary arteries. The 
Pittsburgh EDC study provides some reassurance that CAC reflects atherosclerosis, as there 
was a strong correlation between CAC and both clinical disease and cardiovascular risk 
factors (Olson JC 2000). A number of angiographic and autopsy studies further suggest more 
extensive disease in Type 1 diabetic than in nondiabetic cohorts (Crall FV 1978, Valsania P 
1991, Pajunen P 2000), as does a study from Oslo (Larsen J 2002) that demonstrated, using 
intravascular ultrasound, that all T1D subjects studied had significant coronary intimal 
thickening. Coincident with changes in intima-media thickening (IMT) are changes in arterial 
compliance and distensibility. Endothelial dysfunction has been seen in teenage subjects 
within the first decade of Type 1 diabetes onset (Jarvisalo MJ 2004, Singh TP 2003). Thus, 
these studies confirm that changes in vascular structure and function occur early in the course 
of Type 1 diabetes 
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2.2.1. Prognostic factors 
 
Although the increased risk of premature heart disease in Type 1 diabetes has been recognized 
for some time, the underlying pathogenesis is still poorly understood. The most likely factor, 
a priori, to account for this increased risk is hyperglycemia. However, despite recent evidence 
from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes 
Interventions and Complications (EDIC) study that prior intensive glycemic control reduces 
cardiovascular disease, the epidemiologic association between glycemia and coronary artery 
disease (CAD) is surprisingly weak. 
In the 10-year follow-up report from the EDC study, lipids (both HDL and non-HDL 
cholesterol), hypertension, smoking, and a marker of inflammation, i.e., total white blood cell 
count, predicted total CAD events with some variation according to the type of CAD event 
(e.g., depressive symptomatology predicted angina, whereas nephropathy and a measure of 
insulin sensitivity [estimated glucose disposal rate, eGDR – including waist-to-hip ratio, 
hypertension, and HbA1 based on a substudy of 24 subjects who underwent 
hyperinsulinemic-euglycemic clamp] predicted hard events). Earlier sex-specific analyses 
(Lloyd CE 1996) suggested that nephropathy was a particularly strong CAD risk factor in men, 
whereas waist-to-hip ratio and hypertension predominated in women. Intriguingly, glycemic 
control was not a predictor of CAD, either as a baseline predictor (Orchard TJ 2003) or using 
a cumulative glycemic exposure measure (Forrest KY 2000). 
EURODIAB, with an 8-year follow-up, largely confirmed these findings, although sex-
specific results differed, with proteinuria being independently predictive of CAD in both 
sexes and waist-to-hip ratio in men (Soedamah-Muthu SS 2004). Again, HbA1c was not 
independently associated with either events or left ventricular hypertrophy (Giunti S 2005). 
Case ascertainment varied across studies, with ECG abnormalities responsible for more than 
half the events in EURODIAB, compared with only 19% in EDC. 
The WESDR also confirmed these findings, where a more limited range of standard risk 
factors supplemented with detailed retinal characteristics also predicted cardiovascular events, 
although nephropathy appeared to confound these associations and emerged as a stronger 
predictor (Klein BEK 2004). HbA1c similarly showed only a weak association with MI 
(p=0.08) and no association with angina. 
Hyperglycemia has in virtually all studies shown only a weak relationship with CAD events. 
One exception is a small study (Lehto S 1999) of older-onset Type 1 diabetic Finnish subjects 
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without nephropathy. Further exploration of the Pittsburgh EDC and WESDR studies indicate 
that glycemia does strongly predict peripheral arterial disease (Olson JC 2002), amputation 
(Moss SE 1999), and stroke (Klein BEK 2004) but only weakly contributes to the 
development of CAD. There are number of hypotheses explaining this finding, but the exact 
cause of the less role of glycemia is still unknown.  
Beside the relatively well known traditional risk factors described above, there are also 
specific risk factors heavily studied in Type 1 diabetes. First, nephropathy clearly emerges as 
a major predictor, as has been recognized for many years (Jensen T 1987, Krolewski AS 1985) 
and repeatedly confirmed (Tuomilehto J 1998, Torffvit O 2005). However, even without 
nephropathy, CAD rates in Type 1 diabetes are still greatly increased (Krolewski AS 1985). 
Another complication often implicated in CAD risk is autonomic neuropathy (Veglio M 2002). 
Numerous mechanisms may account for premature cardiac death in CAD including 
associations with subclinical but advanced coronary atherosclerosis, abnormalities in coronary 
vasomotor capacity, changes in systolic and diastolic function, and lastly, life threatening 
arrhythmia, the threshold for which is lower in the setting of a relative increase in sympathetic 
tone, a situation commonly seen in diabetic individuals with sympathovagal imbalance. 
Over the past decade, atherosclerosis has increasingly been considered, at least partly, an 
inflammatory disease (Ross R 1999). Several newly recognized factors may contribute to this 
development (Jenkins AJ 2004, Ross R 1999, Baynes JW 1999). E.g. the oxidative 
modification of LDL, and the immune response it produces, may be one of these key factors, 
as an association between antibodies to oxidized LDL and incident CAD has been reported 
(Orchard TJ 1999). The resulting immune complexes may induce foam cell formation and 
damage the endothelium (Lopes-Virella MF 1992). The adherence of monocytes is also a key 
step in this process (Ross R 1999), and it is of interest that E-selectin shows a strong, 
independent prediction of heart disease in Type 1 diabetes (Costacou T 2005). Other 
regulators of adhesion molecules include cytokines, such as tumor necrosis factor-α (TNF-α), 
interleukin (IL)-6, and IL-1β (Bevilacqua MP 1993). These and other markers of 
inflammation have not been extensively studied in the development of CAD. 
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2.2.2. CAD prognosis and revascularization 
 
Coronary artery disease (CAD) is the major complication of both Type 1 and Type 2 diabetes 
mellitus. Among most white populations, approximately 75% of those with diabetes will die 
of cardiovascular disease (Laakso M 1997). Haffner and colleagues suggested that those with 
diabetes alone had the same risk of a future heart attack as did those without diabetes who had 
had a myocardial infarction (MI) (Haffner SM 1998). Although other data suggest that people 
with diabetes alone are not at such high risk, there is universal agreement that the coronary 
risk in those with diabetes is 2–4 times greater than in those without diabetes (Stamler J 1993). 
This finding holds true regardless of the nationality, ethnic, or age group to which one 
belongs. In addition to this much greater risk of having an MI, diabetes greatly increases the 
postinfarction mortality, case-fatality, and 5-year mortality rates (Miettinen H 1998 and 
Herlitz J 1988). Thus, it is vital to undertake all measures that will prevent the occurrence of 
the first heart attack as well as the recurrence of heart attacks. 
Modern coronary revascularization strategies are based on the results of studies conducted in 
the 1970s and 1980s defining the benefit of coronary artery bypass graft (CABG) surgery 
compared with medical therapy alone for the treatment of coronary artery disease (CAD) 
(Detre KM 1977, European Coronary Surgery Study Group 1982, CASS Investigators 1983). 
These early studies demonstrated that the patients most likely to benefit from aggressive 
revascularization were those with baseline characteristics indicative of a poor prognosis, 
including severe angina, triple vessel disease, left main CAD (Takaro T 1982), left ventricular 
dysfunction, and manifestations of severe ischemia (Yusuf S 1994). With the development and 
increased use of PTCA (balloon angioplasty) in the early 1980s, investigators turned their 
attention from indications for revascularization to determination of the optimal form of 
revascularization among patients presenting for a procedure. Studies of the Duke University 
cardiovascular database (Jones RH 1996) identified a gradient of benefit associated with 
PTCA or CABG that was dependent on, and correlated directly with, the extent and location 
of coronary stenoses. 
The relative advantages and disadvantages of each procedure provided the impetus for several 
multicenter, randomized trials comparing PTCA with CABG in patients with multivessel 
disease. Among nearly 5,000 patients with multivessel CAD amenable to either PTCA or 
bypass surgery, long-term survival and survival free of myocardial infarction (MI) were 
equivalent with either intervention, either separately or in total. With similar quality-of-life 
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measures and employment status between groups (Mark DB 1994), the major difference 
found between these revascularization strategies was the increased need for repeat 
revascularization among patients undergoing a primary strategy of angioplasty. Early 
postoperative cognitive impairment, recognized as an important sequela of cardiopulmonary 
bypass (Kolkka R 1980), was not prospectively assessed in these early studies, although long-
term differences were not seen in a small subset of patients randomized between surgical and 
percutaneous revascularization (Hlatky MA 1997). Given the overall results of these studies, 
PTCA was thought to be a reasonable initial strategy in selected patients with multivessel 
CAD. However, the publication of the largest of these trials, the Bypass Angioplasty 
Revascularization Investigation (BARI) (The BARI 1996), cast doubt on the generalizability 
of these findings to all patients meeting criteria in these studies, particularly patients with a 
history of treated diabetes mellitus. 
A particularly poor outcome after an MI in diabetes has led to the search for the optimal way 
to treat people with diabetes who have CAD. The original BARI trial examined the type of 
coronary intervention, percutaneous coronary intervention (PTCA) or coronary artery bypass 
graft surgery (CABG) that may be optimal for those with CAD. In 1996, the BARI 
investigators found that an initial strategy of CABG, as compared with PTCA, significantly 
improved five-year survival among patients with medically treated diabetes (The BARI 1997). 
A later analysis found that in those with diabetes, coronary artery bypass grafting reduced the 
death rate in those who had an MI and also, but less so, in those who did not have an MI 
(Detre KM 2000). This analysis identified two major ways in which CABG protected patients 
with diabetes. First, there was a strong protective effect of CABG with respect to survival for 
the relatively few patients with diabetes who had a spontaneous Q-wave myocardial infarction 
during follow-up. Second, CABG moderately reduced mortality among the majority of 
patients with diabetes who remained free of myocardial infarction during follow-up. Thus, the 
type of revascularization (CABG) and the presence of spontaneous Q-wave myocardial 
infarction interacted with one another in a manner that resulted in greater protection in 
patients with diabetes. Among the patients without diabetes the protective effect of CABG 
was substantially less (and was not significant), regardless of whether the patients had a 
myocardial infarction (Detre KM 2000). However, it left open the question of whether those 
with diabetes whose coronary disease can be managed medically would have a better outcome 
with initial medical or revascularization treatment.  
The revascularization arm of the BARI 2D investigation determined that an early invasive 
revascularization procedure, combined with aggressive and comprehensive medical 
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management, reduced mortality (The BARI 2007). There was no significant long-term 
disadvantage regarding mortality or myocardial infarction associated with an initial strategy 
of PTCA compared with CABG. Among patients with treated diabetes, CABG conferred 
long-term survival benefit, whereas the 2 initial strategies were equivalent regarding survival 
for patients without diabetes (The BARI 2007). 
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2.3. Nephropathy in Type 1 diabetes 
 
Diabetic nephropathy remains the major cause of end-stage renal failure in the Western world. 
It has basically three stages depending on the patient’s albumin excretion rate (AER) which 
has been widely used for diagnosis. The early stage of nephropathy is microalbuminuria 
(AER: 20-200 µg/min) while overt nephropathy diagnosed with AER>200 µg/min. Renal 
failure with proteinuria is the end stage of nephropathy when renal function can be also 
seriously damaged and some form of renal replacement therapy is usually needed. 
Although albumin excretion rate (AER) (Mogensen CE 1984) and glycaemic control (Warram 
JH 2000) are important risk factors, and hyperlipidaemia (Fried LF 2001) is thought to 
enhance kidney disease progression, these factors alone do not adequately explain the inter-
individual variation in risk of developing nephropathy. 
 
2.3.1. Early microalbuminuria 
 
Microalbuminuria (MA) is an important early marker of risk for diabetic renal disease. In 
adults with Type 1 diabetes, between 20 and 80% of subjects with MA are expected to 
progress to severe renal disease (Viberti GC 1982, Almdal T 1994, Watts GF 1991). MA is 
also associated with increased risk for cardiovascular disease and early mortality (Rossing P 
1996, Borch Johnsen K 1985). The development of MA is linked to duration of diabetes in 
adults (9–11), and it is therefore less common in children and adolescents, for whom 
prevalence rates vary between 4 and 21% (Quattrin T 1995). In children, as in adults, the 
development of MA appears to be related to glycemic control and duration of diabetes 
(Davies AG 1985, Quattrin T 1995). However, estimates of the prevalence of MA during 
childhood are confounded by the effects of puberty, as indicated by the documentation in 
several studies that MA is rare before puberty, even in individuals with diabetes of long 
duration (Norgaard K 1989, Rudberg S 1993). Furthermore, most studies of MA in children 
have been cross-sectional, with only a few being longitudinal (Almdal T 1994, Rudberg S 
1993). When longitudinal studies have been undertaken, they have been clinic- rather than 
population-based, and the sample sizes have been relatively small (Barkai L 1998, Jones CA 
1998). Determination of the prevalence of MA in relation to age, sex, duration of diabetes, 
glycemic control, and puberty and of the predictive value of MA in childhood was purposed 
in a large prospective population-based study (Schultz CJ 1999). These data confirm that the 
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cumulative probability of developing MA during childhood is related to sex, HbA1c, duration 
of diabetes, and pubertal status. Differences in pubertal status have a profound effect on the 
prevalence of MA, and that before puberty, there is a latent period followed by a more rapid 
development of MA after pubertal onset. 
 
2.3.2. Overt nephropathy 
 
Overt diabetic nephropathy (ON) carries a high risk of mortality in Type 1 diabetes not only 
in its own right (DERI group 1990), but also as a risk factor for coronary artery disease 
(CAD) and considered to be as an important stage before end-stage renal failure.  
Incidence rate of overt nephropathy increases linearly in the EDC study reaching 2% by 28 
years of diabetes duration which is higher than those reported from Linkoping (Nordwall M 
2004), but very consistent with recent Steno data (Hovind P 2003). A major shift in the 
incidence pattern of ON has likely occurred compared with the earlier Steno data (Kofoed-
Enevoldsen A 1987). With loss of the “16-year peak,” it is important to note that incidence is 
only being delayed until the later years. After 20 years’ duration, the incidence is in fact 
higher in the more recent EDC data than the earlier Steno data. The explanation for the much 
lower Linkoping rates is undetermined but may relate to methodological differences in 
follow-up, as well as reflecting a truly lower level of complications and better glycemic 
control (Nordwall M 2004). 
The nature of ON’s association with CAD is intriguing, for despite the strong association seen 
in the initial reports from the Steno Clinic (Borch-Johnsen K, 1987), recent observations from 
both the United States (Forrest KY-Z 2000) and Europe (Koivisto VA 1996) suggest the 
association is largely, if not totally, explained by disturbed vascular disease risk factors, 
notably blood pressure, lipids/lipoproteins, inflammatory markers, and smoking. ON also 
appears to be a stronger risk factor for CAD in men than in women with Type 1 diabetes 
(Forrest KY-Z 2000). 
Several studies provide support for an insulin resistance-renal link in Type 1 diabetes. Yip et 
al. have reported that T1D subjects with MA had significantly lower glucose disposal during 
euglycemic-hyperinsulinemic clamp studies than did matched controls, even after accounting 
for blood pressure and body mass index (Yip J 1993), while De Cosmo et al. drew attention to 
the high prevalence of CAD risk factors in parents of Type 1 diabetes subjects with 
albuminuria (DeCosmo S 1997). These authors also recently suggested that the rate of 
progression of ON may be predicted, in Type 1 diabetes, by a variant of an inhibitor of insulin 
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signaling PC1 glycoprotein (DeCosmo S 2000). A further set of data also suggest that the 
angiotensin-converting enzyme insertion/deletion (ACE I/D) polymorphism is associated with 
predisposition to both ON in Type 1 diabetes and to insulin resistance (Panahloo A 1995). 
The evidence of whether ACE inhibition improves insulin sensitivity and glucose tolerance is 
also controversial with some reports showing no effect (Jandrain B 1992), while others 
suggest an improvement in insulin sensitivity and glucose levels with use of ACE inhibitors 
(Pollare T 1989). 
The major findings in the 10-year follow-up data of the Pittsburgh Epidemiology of Diabetes 
Complications Study, a well-characterized population-based cohort of Type 1 diabetes 
patients, are the clear demonstration that insulin sensitivity (measured by an estimation – 
eGDR) is the predominant predictor of ON along with white blood cell count and that blood 
pressure (beyond any association with eGDR) and lipids appear to only predict in the short 
term (Orchard TJ Diabetes 2002). This suggests that the latter mainly act as late-stage 
accelerators or precipitators rather than underlying etiologic factors. In addition, this study 
also presents a novel way to explore genetic susceptibility (Orchard TJ Kid Int 2002). Urinary 
albuminuria (AER) was found to be a strong independent predictor of overt nephropathy in 
both univariate and multivariable analyses in the EDC study (Yishak AA 2006), in agreement 
with earlier reports (Mogensen CE 1984). 
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2.3.3. End-stage renal disease and renal replacement therapy 
 
End-stage renal disease is the final stage of nephropathy when renal function is usually 
seriously impaired. Thus, life-quality and life expectancy becomes very poor in patients 
making this entity which is one of the most severe complications of Type 1 diabetes. 
Hasslacher at al. have reported that the prevalence of proteinuria, 25 years after diagnosis of 
T1D, was about 40% (Hasslacher C 1989). Krolewski et al. showed that about 40-50% of 
subjects with T1D developed diabetic nephropathy in their life time (Krolewski AS N Engl J 
Med 1987). The same author reported also that approximately 30 % of T1D have ESRD at 40 
year after onset. (Krolewski M 1996). Klein et al. reported that cumulative incidence of renal 
insufficiency (serum creatinine >=2.0 mg/dl) and ESRD in a population-based cohort from 
Wisconsin was 14.4% at 10 year (Klein R 1999). In the Pittsburgh Epidemiology of Diabetes 
Complications study based on children diagnosed with T1D between 1950 and 1980, the 
cumulative incidence of renal failure at 25 years has declined from 21% to 9% for those 
diagnosed in the 1950’s to the 70’s, respectively. (Orchard TJ Diabetes 2002). 
Because diabetes is the leading cause of end-stage renal disease (ESRD) (Centers for Disease 
Control and Prevention 2005) and testing for proteinuria is widely recommended for patients 
with diabetes, the sensitivity of albuminuria in identifying persons at risk of progressive loss 
of kidney function is utmost important in all types of diabetes. A report from the UK 
Prospective Diabetes Study (UKPDS) concerning patients with newly diagnosed Type 2 
diabetes indicated that 51% of patients who developed renal impairment did not have 
preceding albuminuria (Retnakaran R 2006). Similar findings were observed in the 
DCCT/Epidemiology of Diabetes Interventions (EDIC) Study, in which a substantial 
proportion (44%) of individuals with Type 1 diabetes and eGFR less than 60 mL/min/1.73 m2 
presented with normal AER (Molitch ME 2006). In the EDC study, contrary to previous 
reports, development of ESRD without albuminuria may occur rarely in patients with Type 1 
diabetes (Costacou 2007). Individuals with this manifestation in this cohort used greater 
insulin doses per body weight despite insulin sensitivity (according to the eGDR) and HbA1c 
levels similar to persons with albuminuria when seen in our study. 
After patients had ESRD, mean survival after the introduction of renal replacement therapy 
(RRT) is extremely poor (Matsushima M 1995, McCrary RF 1981). However, a declining 
mortality has been reported in other studies after the introduction of kidney or pancreas-
kidney transplantation (Becker BN 2000, Wolfe RA 1999). Little information is available, 
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however, regarding the exact incidence rates of ESRD and its related mortality in childhood-
onset Type 1 diabetes from population-based studies. 
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3. Objectives 
 
The aims of the present studies were to determine and analyze cause-specific mortality and 
complication related survival patterns in patients with T1D, specifically: 
 
1. to determine mortality rates related to acute and chronic diabetes complications and to 
analyze to role of CAD and nephropathy in the underlying causes of death in the 
Pittsburgh Metropolitan Area (Allegheny County, Pennsylvania, USA) 
 
2. to compare two T1D populations living under considerably different social and health 
care circumstances in terms of cause-specific mortality patterns (Allegheny County 
registry vs Havana cohort) 
 
3. to estimate the relative mortality of patients with T1D as compared to the general 
population in relation to age and duration of diabetes, and to analyze the effects of age 
at diagnosis, year of diagnosis in both populations 
 
4. to examine racial (Caucasian, African-American, Hispanic) and gender differences in 
cause-specific mortality in both cohorts 
 
5. to analyze the incidence and predictors of CAD and different stages of nephropathy 
(MA, ON, ESRD), as well as the survival after these complications, and their invasive 
treatment (coronary revascularization (PTCA, CABG) and renal replacement therapy 
(dialysis, kidney transplant)) in Allegheny County. 
  26
4. Patients and methods 
 
4.1 The Diabetes Epidemiology Research International (DERI) Study –  
Epidemiology of Type 1 Diabetes Mortality in Four Countries 
 
The DERI study is one of the largest population based prospective cohort study of T1D 
mortality which was initiated in 1986 to test the hypothesis of cross-population differences in 
diabetes prognosis. The study has evaluated mortality in comparable population-based cohorts 
from four distinctly different countries (USA, Finland, Japan, Israel). These areas were 
selected because they were racially and culturally diverse, had advanced diabetes-care 
systems, had major cross-population differences in the risk of developing childhood onset 
diabetes and had comparable population-based cohorts. Of particular importance, they were 
also different patterns in the background mortality.  
 
4.1.1. Identification of comparable cohorts 
 
This study evaluated four population-based cohorts of T1D cases from Japan, Israel, 
Allegheny County, Pennsylvania, and Finland. In order to make cross-country comparisons, 
the Allegheny County, Pennsylvania cohort was taken to be representative of the United 
States. 
Inclusion in the study was based on the following criteria: 1. subjects were diagnosed with 
diabetes before 18 years of age between January 1, 1965 and December 31, 1979; 2. placed on 
insulin at diagnosis; 3. residing in the geographic areas listed above. 
Persons were excluded if they developed diabetes from a secondary cause, i.e., diabetes 
associated with cystic fibrosis or Down's syndrome and steroid-induced diabetes. 
Eligible individuals in Israel, Allegheny County, and Finland were identified from incidence 
cohorts. In contrast, the individuals from Japan were identified from two prevalence cohorts, 
and follow-up was identified as of the date each prevalence cohort was identified rather than 
at the date of diagnosis. The first cohort consists of individuals who were diagnosed between 
January 1, 1965, and December 31, 1969, and were alive as of January 1, 1970. The second 
cohort consists of those who were diagnosed between January 1, 1970, and December 31, 
1979, and were alive as of January 1, 1980. In order to make the three incidence cohorts 
comparable to the prevalence cohorts in Japan, this "alive as of' criterion was applied to the 
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three incidence cohorts. Consequently, individuals who fulfilled the criteria of the first cohort 
and died before January 1, 1970, and those who fulfilled the criteria of the second cohort and 
died before January 1, 1980, were excluded.  
 
The cohort of Allegheny County, Pennsylvania, USA: 
Allegheny County is located in southwestern Pennsylvania, which hosted a population of 
approximately 1.6 million in 1970 and 1.3 million in 2000 with Caucasians accounting for 
more than 80% of the population. The city of Pittsburgh is the seat of the county as well as the 
western Pennsylvanian region. 
Persons with T1D in Allegheny County were identified from an incidence registry developed 
through the review of hospital records and validated by contact with pediatricians in the 
community. Ascertainment of the cases was accomplished by retrospective review of hospital 
records. For this registry, the degree of ascertainment is well over 95 percent. To be included 
in the registry, the patient had to be on insulin therapy at hospital discharge. Allegheny 
County has one large children’s hospital (Children’s Hospital of Pittsburgh) and 25 general 
hospitals that possibly would see young diabetics. All but one of the hospitals were surveyed 
(permission was not obtained for one small hospital). Few cases were likely to have been 
missed by this omission because of its size. In addition, physician records from two large 
private practices were also reviewed. Monthly listings of discharges as compiled by the 
Hospital Utilization Project were carefully inspected in each hospital and records were 
requested for all discharges where diabetes was the primary diagnosis and the patient was less 
than 20 years old. For each case, demographic information, date of diagnosis, referring and 
attending physicians, history of onset of symptoms and family history of diabetes were 
recorded. Subjects identified only from readmission records were included only if verification 
of residence was obtained from municipal telephone books for the year of diagnosis. Hospital 
records at the time of diagnosis were obtained for over 90% of the cases. 50% of T1D cases 
were diagnosed at the Children’s Hospital. Another 20% diagnosed at other hospitals were 
seen later in Children’s Hospital’s diabetes programs. Thus, although there were 26 hospitals 
in the county, over 70% of the diabetics were eventually seen at Children’s Hospital and 
could be identified through review of that hospital’s records. To check the completeness of 
ascertainment, all pediatricians (approx. 150) in Allegheny County were requested to identify 
children under their care who met the criteria for inclusion in the registry. This survey 
revealed that all children fulfilling the criteria were seen in a hospital. These results gave 
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confidence that an accurate hospital record review provides virtually complete ascertainment 
of cases developing in the county. 
From the Allegheny County registry, 1,075 eligible cases were identified as of January 1, 
1980. 
 
4.1.2 Procedures for mortality and complications 
 
In order to follow up cases, permission was first obtained from the hospital at diagnosis to 
contact the attending or referral physician for each eligible case. Upon approval, permission 
was then obtained from the attending/referring physician to approach patients, who were 
contacted by letter, and, where needed, by phone at initial follow-up conducted in 1985. To 
ascertain living status, the same follow-up procedure was done as of 1990. As of January 1, 
1999, living status was updated with the addition of a complication survey with nine new 
questions concerning renal, retinal, cardiovascular and peripheral artery status (Appendix 1.) 
This questionnaire included yes/no answer possibilities to the complication questions with 
asking also about the date of complications’ onset. Specifically, the diagnosis of coronary 
artery disease (CAD) was based on history of myocardial infraction and/or revascularization 
therapy as well as CAD related death confirmed by death certificate. Similarly, onset of end-
stage renal disease (ESRD) was defined as the introduction of renal replacement therapy 
(dialysis or transplantation). Transplant recipients also were asked if they underwent kidney 
transplantation or pancreatic-kidney transplantation. 
Re-contact was first made by a letter with a questionnaire form to sign giving consent. If the 
subjects did not respond to this questionnaire, they were contacted by phone. Names of 
patients for whom the investigators could not ascertain their living status by mail or phone 
contact were submitted to a National Death Index (NDI) search to see if these patients are 
deceased or not. For patients whose deaths were confirmed by NDI, death record follow back 
investigation was conducted to obtain the permission from next of kin to obtain the medical 
records surrounding death for in hospital deaths and coroner's and/or autopsy report for out of 
hospital deaths. 
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4.1.3. Validation process of causes of death 
 
For the cases identified as having died attempts were made to collect data from several 
sources for events surrounding the death. First of all the death certificates were obtained. In 
addition, copies of the hospital records surrounding the death and autopsy records (if 
available) were obtained in order to establish the cause of death more firmly. A standardized 
set of information abstracted from the medical records was created by trained personnel, 
mainly by the co-investigator of the study. This person had a medical degree and had also a 
good understanding on the field of diabetes treatment and research. The information sheet 
collected the past medical history and all the details concerning the death. The past medical 
history focused particularly on kidney and cardiovascular disease, previous admissions for 
diabetes control, and evidence of potential self-destructive behavior. The second set of 
information consisted of circumstances surrounding the death and complication status, with 
particular focus on kidney disease, current method on insulin treatment, and recent 
cardiovascular events. Details of recent infections were also collected. In the case of accidents 
and suicides, further relevant information was documented. In the event that a hospital record 
was not available, similar information was obtained from physician records, medical/legal 
reports, or, as a last resort, informant interviews. In this case, a study physician (usually the 
principal investigator or the co-investigator) or nurse asked about the circumstances at death 
if the next of kin previously agreed to talk. In case if they felt uncomfortable at any point they 
were free to stop the interview. Autopsy data were also sought for individuals who had been 
hospitalized and underwent an autopsy. The percentage of subjects autopsied was different in 
the participant countries, but was about 50% in Allegheny County in contrast with Finland 
where around 90% of subjects were autopsied. For those who died outside hospital, 
alternative sources of information were sought. Coroner’s/medical examiner’s investigations 
and police reports were obtained, and detailed abstracts were made by trained abstractors. 
Standardized data were also obtained from autopsy reports. In all cases, details from death 
certificates were fully abstracted. Standardized forms were used for all data collection and 
were transmitted to the central coordinating center in Pittsburgh, Pennsylvania.  
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Mortality classification: 
The objectives of the mortality classification, with all available information, were to 
determine 1. the most likely underlying cause of death, 2. the order of importance of all other 
contributing causes of death, and 3. the role of diabetes in causing the death. 
Given the complex interaction of various potential causes of death, e.g., kidney failure and 
myocardial infarction, it was decided to have the secondary causes listed in an ordered 
manner according to the role in causing death to permit standard combinations of causes of 
death. A set of standardized rules for classification of death was developed during the review 
process. Whenever a new rule was adopted, it was applied to any previous relevant case. For 
example, although diabetes is a recognized risk factor, it was decided not to list diabetes as a 
contributing cause unless it contributed to the death in other ways (e.g. by the development of 
diabetic ketoacidosis). 
The evaluation of the role of diabetes was deemed as being critical to understanding mortality. 
The following three levels of contribution of diabetes to death were designated: level 1, 
diabetes caused the death (i.e. death would have occurred from a diabetes cause regardless of 
other conditions that were present); level 2, diabetes contributed significantly to the death (i.e. 
deaths would not have occurred if the patient had not had diabetes, but another potentially 
lethal condition was present and also contributed); and level 3, diabetes contributed 
marginally to the death (i.e. diabetes was not thought to be essential to explain the death but 
played a role). To facilitate an understanding of the process leading to death, schematic 
diagrams were drawn for each death by the reviewers. 
The review procedure was handled as follows. A Mortality Classification Committee (MCC) 
supervised the validation in each case. The MCC consisted of four physician members, one 
from each country and an independent chairman. Each member reviewed all collected data 
before each mortality review meeting and completed a review form that addressed the three 
designated objectives. For each death the MCC member wrote a brief summary in English of 
the circumstances leading to death without making any judgment about their interpretation of 
the underlying cause. In this manner, a standardized set of information was coherently 
collated for each committee member, although members were free to interpret the clinical 
data recorded in the forms independent of the summary. The specific methods of operation 
was fully described and made available for all committee members. All deaths were presented 
by the member from the respective country and reviewed by the committee. Discussion then 
took place as to the key points underlying cause of death, order of importance of contributing 
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causes, and the role of diabetes. If after discussion, all four members did not come to a 
unanimous agreement, the independent chairman had a casting vote. This, however, rarely 
occurred. This procedure allowed that the patterns of death across countries became directly 
comparable. Though the committee members could not be blinded to the deceased patient’s 
country of origin, the standardized approach and full discussion ensured, so far as possible, to 
immunize them from any potential biases, that may have arisen from knowing the county of 
origin.  
 
4.1.4. Ethical consideration 
 
The whole study procedure was approved by the Institutional Review Board of the University 
of Pittsburgh. All information gathered in this study was protected against release to 
unauthorized people. Any information, which carried personal identifying material, was kept 
in locked files. Identity of the patients has not been revealed in any description or publication 
of this research. 
Contacting next of kin was initially conducted by mail. If the next of kin did not want to sign 
the release form, they could refuse it by checking the box at " I do not wish to sign" on the 
contact letter. If the next of kin did not respond to the letter, an experienced physician or 
nurse called them and asked them if they received the letter from us and if they had agreed to 
sign a medical release. When contacted by phone, a trained physician (usually the 
investigator/reviewer) or nurse asked about the circumstances at death if the next of kin 
agreed to talk. They were told that if they felt uncomfortable at any point they were free to 
stop the interview and the investigators recontacted them only at their invitation. 
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4.2. The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study 
 
The EDC study is a representative (Wagener DK 1982) originally 10-year prospective study 
examining the prevalence, incidence, interrelationships and risk factors of the various 
complications of Type 1 diabetes, now entering its 20th year of follow-up. The EDC baseline 
examinations were conducted between 1986 and 1988, and participants were examined 
biennially thereafter. A total of 1,124 patients were eligible for the study, having been 
diagnosed or seen within 1 year of diagnosis at Children's Hospital of Pittsburgh between 1 
January 1950 to 31 May 1980 and living within 100 miles or 2.5 hours from Pittsburgh. All 
were receiving insulin therapy at the time of initial discharge from the hospital. Of the 1,124 
eligible patients, 145 (13%) had died before baseline (1986–1988) and 191 (17%) chose not 
to participate. A total of 788 (70%) participated, with 130 (16%) providing survey 
information only. Thus, 658 subjects met eligibility criteria (325 women and 333 men) and 
participated in the baseline examination in 1986 to 1988 where the mean age was 28 years 
and diabetes duration was 19 years. Those refused clinic attendance completed a medical 
history questionnaire thereafter.  
 
4.2.1. Patient selection for the CAD and ON complication study 
 
Four hundred and fifty-four participants (223 women, 231 men, mean age: 32 ± 8 years, mean 
duration of diabetes of 23 ± 8 years) were selected who attended the third biennial follow-up 
visit (1990-1992). The incidence data of CAD and ON were collected between the third and 
sixth visits (1990-1998), while clinical and metabolic risk factors were gathered from the third 
cycle of examinations in 1990 to 1992. The average follow-up time was six years. 
 
4.2.1.1. Clinical evaluation and metabolic investigation 
 
Clinical evaluation and definition of T1D complications used in the EDC study have been 
reported in details (Orchard TJ 1990 I-II). Body-mass index (BMI) was calculated as body 
weight divided by height squared. Waist circumference was measured on standing subjects 
midway between the lowest rib and the iliac crest. Hip circumference was measured over the 
widest part of the gluteal region and the waist to hip ratio (WHR) was calculated. Blood 
pressure was measured according to a standardized protocol (Hypertension Detection and 
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Follow-up Program) (Borhani NO 1976). Hypertension (HTN) was diagnosed as use of blood 
pressure medication or a level of 140/90 mmHg or above. Those who had ever smoked at 
least 100 cigarettes and still smoked at baseline were considered to be smokers. 
Coronary artery disease was defined by a history of myocardial infarction, confirmed by 
electrocardiographic changes (Minnesota codes 1.1 or 1.2) at time of examination, or review 
of previous medical records by use of standardized criteria (Orchard TJ 1985), angina 
diagnosed by the clinic physician, ischemic ECG (Minnesota codes 1.3, 4.1, 4.2, 5.1, 5.2, 7.1) 
or coronary artery stenosis ≥50% by angiogram. Overt nephropathy was defined by renal 
failure or an albumin excretion rate >200 µg/min in at least two of three timed urine 
specimens. 
Glycosylated hemoglobin (HbA1) was originally determined with saline-incubated blood 
samples and microcolumn cation-exchange chronomatography (Isolab, Akron, OH). However, 
from October 1987 the technique was changed to high-performance liquid chromatography 
(Diamat, Bio-Rad, Hercules, CA) which is relevant from the CAD/ON complication subgroup 
analysis. Serum cholesterol and triglyceride levels were determined enzymatically. High-
density lipoprotein cholesterol was determined by a heparin and manganese procedure. Low 
density lipoprotein cholesterol was calculated with the Friedewald equation if triglycerides 
were <4.5 mmol/l. Fibrinogen levels were performed via a biuret colorimetric procedure and a 
clotting method and creatinine with an autoanalyzer (Ectachem 700xr, Kodak, Rochester, 
NY). PAI-1 and tPA-PAI-1 concentrations were determined by an ELISA procedure 
(American Bioproducts Co. Parsippany, NJ, USA). The PAI-1 assay measured total 
circulating PAI-1 (i.e. free or complexed with tPA). The intra- and interassay coefficients of 
variance for PAI-1 were 5.9% and 9.4%, respectively, and for tPA-PAI-1 8% and 11%, 
respectively. In this subgroup analysis, there were 13 and 15 individuals in which PAI-1 and 
tPA-PAI-1, respectively were not obtained for technical reasons. Beck Depression Inventory 
was also used to assess psychosocial status (Beck AT 1988). Estimated Glucose Disposal Rate 
(eGDR) was calculated based on equation (eGDR=23.31-12.22(Waist to Hip Ratio)-
3.29(Hypertension)-0.57(HbA1)) derived from hyperinsulinemic-euglycemic clamp studies 
(Williams D 2000) to determine insulin resistance in a subgroup (n=24) of the EDC 
population.  
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4.2.1.2. Ethical considerations 
 
The EDC protocol was approved by the University of Pittsburgh Institutional Review Board, 
and all patients gave informed consent. 
 
4.2.1.3. Statistical analysis 
 
For those variables not normally distributed (i.e. PAI-1, tPA-PAI-1, triglycerides, Beck score, 
white blood cell counts) logarithmic (log10) transformation was performed. Two-sided 
Student’s t-test and the Mann-Whitney U-test were used to examine differences in PAI-1, 
tPA-PAI-1 and risk factors between incident cases and non-cases. Chi square test was applied 
to reveal differences in categorical variables. Spearman’s rank correlation and partial 
correlation were used to assess univariate associations between baseline variables. 
Cox regression modeling (forward stepwise method; p-value for entry: 0.05, removal: 0.1) 
was used to examine relationships between T1D complication status and independent 
variables (e.g. PAI-1, tPA-PAI-1, HbA1, age, triglycerides, hypertension, Beck score, 
leukocyte count, fibrinogen). 
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4.3. Combined cohort of DERI+EDC studies 
 
For wider mortality analyses the patient group of the DERI study was extended with EDC 
individuals based on standardized procedure. Thus subjects involved into the combined cohort 
were identified from two Type 1 diabetes incidence registries, the Allegheny County, PA 
Registry and the Children’s Hospital of Pittsburgh Registry (Dorman JS 1984, Orchard 1990 
I-II). Seven hundred and fifty four subjects came from the Allegheny County registry alone 
(63 of whom were Black), 245 from the Children’s Hospital (5 of whom were Black) and a 
further 262 subjects were members of both cohorts (8 of whom were Black and 1 Asian who 
for analysis is included as Black), giving a total of 1261 subjects. Allegheny county cases 
were identified as described by the DERI study (periodic review of hospital records and 
validated by contact with pediatricians in the community yielding a >95 percent ascertainment 
rate). 
The eligibility criteria for the current combined analysis were: 1. a diagnosis of Type 1 
diabetes between January 1, 1965 and December 31, 1979; 2. age <17 years old at diagnosis; 
3. receiving insulin therapy at discharge from diagnosis hospital admission; and 4. residence 
of Allegheny County, Pennsylvania or living within 100 miles from Pittsburgh at diagnosis. 
Persons were excluded if they had developed diabetes from a secondary cause, e.g. diabetes 
associated with cystic fibrosis, Down’s syndrome, or steroid therapy as described in the DERI 
methods.  
Vital status ascertainment has been described earlier as it follows the procedure seen in the 
DERI study (Nishimura R 2001, Orchard 1990 I-II). Briefly, living status as of January 1, 
1999, was verified by letter or if needed, telephone contact (Allegheny County Registry 
cohort) or by attendance at biennial examinations for the Children’s Hospital of Pittsburgh 
subjects participating in the Epidemiology of Diabetes Complication Study (EDC). The living 
status was determined for 1183 (94 percent) patients of whom 200 have died.  
 
4.3.1. Determination of causes of death 
 
The underlying cause of death was determined by the review of death certificates, hospital 
records, coroner’s records, and autopsy reports using the standardized protocol of the 
Diabetes Epidemiology Research International Group Mortality Classification Committee 
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(DERI) [see in section 4.1.2.] and verified by a committee of physicians based on a 
standardized protocol [see in section 4.1.3.].  
For mortality analysis, the underlying cause of death was grouped into acute diabetes 
complications (deaths from diabetes ketoacidosis, hyperglycemia, hypoglycemia, and 
unspecified coma); chronic complications (deaths from renal, cardiovascular diseases, 
infection and other diabetes related problems), and other causes (deaths from non-diabetes 
related problems, e.g. accident/suicide, cancer and post-surgical complications). 
 
4.3.2. Statistical analyses 
 
Overall, cause-specific mortality rates per 100 000 person years of follow-up and 20-year 
cause-specific rates by sex and race were determined. To assess the temporal trends of cause-
specific mortality, the total cohort was divided into three groups by year of diagnosis (1965–
69, 1970–74 and 1974–79). Temporal trends were also assessed by sex and race. The chi-
square test for trend was used to assess the trend of mortality according to diagnosis cohort. 
Chi square or Fisher’s exact test was used to determine any difference between categorical 
variables. Lifetable analyses by the Kaplan–Meier method were also performed, and the log-
rank test was used to determine the statistical difference between the hazard curves. We used 
Cox proportional hazard models to simultaneously estimate hazard ratios (and 95% 
confidence intervals) for the effects of sex, race, age at diagnosis and year at diagnosis. The 
95% confidence intervals were determined based on the Poisson distribution [14]. Statistical 
analyses were conducted with SPSS software version 12.1 (Statistical Package for the Social 
Sciences, Chicago, IL, USA). A two-sided P-value of less than 0.05 was considered 
statistically significant. 
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4.4 The Havana City cohort 
 
The Havana city cohort is created to determine the survival pattern and the underlying cause 
of death in a cohort of childhood-onset T1D subjects from Havana City Province, Cuba. The 
mortality evaluation based on this cohort was first report of a study performed on a large 
cohort of people with T1D followed up for a long time in a developing country (Collado-
Mesa F 1997). 
A Havana city cohort was defined by age at diagnosis of T1D (<15 years of age), place of 
residence at diabetes diagnosis (Havana City Province), and date of diagnosis (1 January 1965 
to 31 December 1980). 
Inclusion into the cohort began at the onset of T1D, and the patients were followed until they 
died, emigrated, or until 31 December 1991. Emigrated subjects were censored at the date of 
migration. Subjects with unknown status at the end of the study were censored at the date of 
the last medical consultation. 
To estimate the number of subjects in such a cohort, the investigators examined Havana City 
Province data from the National Registry of T1D subjects with onset before 15 years of age. 
This Registry has been running since 1979, and in 1990, it was enrolled as a participating 
center of the World Health Organization (WHO) Multinational Project for Childhood 
Diabetes (DiaMond Project) (WHO DiaMond Group 1990). The average annual number of 
incident cases between 1979 and 1990 in the province was 30. Thus, the estimated number of 
T1D subjects during the 15-year period of cohort formation (1965-1980) is 450, assuming no 
temporal changes in the disease incidence and population demographics. 
The cohort was assembled from several sources. Between 1965 and 1980, there was a single 
health care center (Hospital Dr. Pedro Borras Astorga), where all children were diagnosed 
with T1D and where all children living in Havana City Province attended. At age 15 years, 
they were all referred to another center for teenage diabetes (Diabetics Care Centre, National 
Institute of Endocrinology). In this center, a registry, including all data from the pediatric 
health care center, was maintained. Those on this registry were included in the cohort. 
Some children with T1D may have died before they could be referred to the pediatric health 
care center. Therefore, examined necropsy records of pathology archives at pediatric hospitals 
in Havana City were also examined for the study period. 
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All residents of Cuba have a unique identity number at the Identity Card and Population 
Registry. This number was used to obtain the subjects' vital status at 31 December 1991. All 
deaths and migrations in Cuba are registered here.  
A single National Public Health System has been running in Cuba for more than 35 years, 
providing free medical care and covering the entire population. Death certificates are 
completed by medical doctors for every death in the country. The National System of Public 
Health Statistics collects and produces data of recognized quality. 
Since information on death certificates is imprecise (DERI Study Group Am J Epidemiol 1991, 
Karger S In Prognosis of Diabetes in Children 1989), the investigators attempted to obtain 
more detailed information from clinical records and necropsy reports (if performed), using a 
similar approach to that used by the Diabetes Epidemiology Research International (DERI) 
Epidemiology Mortality Group (see section 4.1.2.) (DERI Study Group Diabetes Care 1991). 
After all deaths in the cohort were identified, attempts were made to obtain copies of the 
medical records (including the last hospitalization if the subject died in a hospital), autopsy 
reports, and death certificates. Standardized forms were used for all data collection. 
Information on cause of death was obtained from death certificates in 90% of deceased 
subjects, from necropsy reports in 64.3%, and from medical records in 31.4%. 
A one-paragraph summary on terminal events was then prepared. The three members of the 
mortality classification committee independently coded the main cause of death and 
secondary causes that contributed to that death. Eventually, all the information was evaluated 
by the committee, which collectively decided the most likely underlying cause of death for 
every deceased subject. 
 
4.4.1. Combined cohort for comparative analysis 
 
For further examine and compare the mortality in Havana, Cuba and in the Allegheny County, 
Pennsylvania, USA, a standardized cohort from these two population-based registries was 
created. Cases diagnosed with T1D between 1965 and 1980 in the Havana cohort and 
between 1965 and 1979 in the Allegheny County cohort were included. The inclusion criteria 
for both registries were: diagnosed by a physician as having diabetes, placed on daily insulin 
injection before the 15th birthday and resident of the registry caption area at the time of first 
insulin administration.  
Cases in Allegheny County cohort were identified from an incidence registry (see section 
4.1.1.). The Havana cohort was assembled with cases from various sources. The Havana 
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registry was validated by comparison to a census of people with diabetes in three health areas 
of about 30,000 inhabitants each. All the cases meeting the inclusion criteria found in the 
community had been previously included in the registry. Therefore the registry was 
considered virtually complete. 
For the analysis of causes of deaths both studies followed the procedures described by DERI 
study (see section 4.1.2.) which included information from death certificates, necropsy or 
coroner’s reports and hospital records. The deaths in the Havana cohort were classified by 
three well-trained physician-members of an ad hoc committee. Deaths in Allegheny County 
were classified by physician members of the DERI Mortality Classification Committee (see 
section 4.1.3.). 
Follow-up started with the onset of diabetes in each individual and ended as of January 1st 
1991, or with death. 
 
 
4.4.2. Statistical analyses 
 
The mortality in the general population in Cuba (Ministerio 1996) and the US (by race) (US 
Census 2000, US Department 1996) in 1980 were used as background mortality in the 
calculation of SMR. Mortality rates and SMR were adjusted by age and sex using the world 
population as standard (M. Segi 1963).  
Life-table analyses were used to examine the mortality rates in both populations by duration 
of diabetes. To determine age-specific mortality rates, the number of deaths that occurred 
within each age group was divided by the number of person-years within that age group. 
Mortality rates per person-year of follow-up by country and race were determined. The 
ethnicity analysis used a breakdown of Allegheny County cohort in Caucasians and African 
Americans; cases from Havana cohort are referred as Hispanics since information on ethnicity 
was unavailable for this analysis. 
Standardized Mortality Ratio (SMR) was also calculated. Survival analysis and Cox 
proportional hazard model were included in the analysis.  
All analyses were conducted using the computer packages SPSS and Stata. 
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4.5 University of Pecs, albuminuria follow-up 
 
To examine early microalbuminuria (MA) in children (age<18 years) with Type 1 diabetes, a 
standardized screening method and 5-year follow-up visits were initiated in 1997 at the 
University of Pecs, Department of Pediatrics.  
Beyond the general metabolic assessment and insulin dose optimization being done during the 
control visits in the hospital, the children underwent regular complication (e.g. 
ophthalmologic) examination which was done by the same person with the same methodology 
throughout the follow-up process.  
 
4.5.1. Clinical evaluation and metabolic investigation 
 
All albumin assays were carried out in the department’s central laboratory. Urinary albumin 
(collected for 24 hour) was measured by immunonephelometry (Turbox nephelometer, 
reagens from Orion Diagnostica, Finland; linearity: 7-150 mg/l, variability by 12 mg/l: CV= 
3.6%, by 128 mg/l: CV=3.9%). Diagnosis of microalbuminuria was based on the results of 
three consecutive 24-hour urine collections (mean AER ≥ 30mg/day). Median-albuminuria 
was defined on the individual basis if the mean AER of the three consecutive measures 
reached the median AER level of the total cohort (≥14.5mg/day). 
Glycemic control was assessed by HbA1c measurement using low pressure cation-exchange 
chronomatography (Bio-Rad DiaSTAT analyzer; measurement range: 4.9-17.2%, 
reproducibility by 6.4%: CV=2.5%, by 10%: CV=2.1%). Long-term glycemia at follow-up 
was evaluated using mean HbA1c values from the previous 5 years (4 measures/year, approx. 
20 values). 
Serum cholesterol and triglyceride levels were determined enzymatically after a 12-hour 
overnight fast.  
Body height and weight were measured in underwear without wearing shoes using Harpenden 
stadiometer for height and a standard calibrated scale for weight measurements. BMI was 
calculated as body weight in kilograms divided by height in meters squared. Blood pressure 
readings were measured by a random-zero sphygmomanometer after a five-minute rest period. 
Daily insulin requirement was calculated as total insulin dose divided by the body weight 
(U/kg). Pubertal staging was performed based on the Tanner-scores (1-5). 
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4.4.2. Statistical analyses 
 
Two-sided Student’s t-test and paired t-test (for longitudinal analysis in those patients 
attended both follow-up visits) were used to examine differences in normally distributed 
continuous variables. Chi square test and trend analysis were applied to reveal differences in 
categorical variables. Pearson’s correlation was used to assess univariate associations between 
variables. Logistic regression modeling was used to examine relationships between MA and 
median-MA status and independent variables.  
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5. Results 
 
5.1. Mortality and underlying causes of death in the Pittsburgh Metropolitan Area 
 
5.1.1. Living status and demographic characteristics 
 
The living status of 94 percent of the total cases involved in the combined (EDC+DERI study, 
n=1261) cohort was confirmed (Table 1.). There were no statistical differences between the 
subjects with confirmed living status and missing cases in age at onset (“mean (SD)” 10.1 
(4.1) vs 10.7 (4.3) years, respectively), mean year at onset (1971.8 (4.1) vs 1971.8 (4.2), 
respectively) or sex (50.3% vs 51.3% male, respectively). However, African-Americans were 
less likely to have verified vital status than Caucasians (84% vs 94%; p<0.001). In terms of 
the demographic characteristics of the study population at follow up, women were 
significantly younger than men (p<0.05). African Americans were also significantly younger 
than Caucasians (p<0.05) and had a significantly shorter duration of diabetes than Caucasians 
(p<0.05). No differences were seen by sex and race in age at onset (10.1 (4.0) years) and in 
year of diabetes diagnosis (1971.8 (4.2)). 
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Table 1. 
Demographic characteristics of the study population at follow- up (1999) by sex and race 
(The combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA registries) 
 
 Male 
N=635 
 
Female 
N=626 
Caucasian 
N=1184 
African 
American 
N=77 
Total 
1261 
Living status 
confirmed  
N (% of total) 
 
595 (94%) 588 (94%) 1118 (94%) 65 (84%)* 1183 (94%) 
Died 
N (% of total) 
 
101 (16%) 99 (16%) 173 (15%) 27 (35%)* 200 (17%) 
 
 
Demographic variables- mean (SD) shown 
 
Age at follow- 
up (years) 
 
36.5 (6.2) 35.7 (6.7)* 36.3 (6.4) 33.7 (7.9)* 36.1(6.5) 
Diabetes 
duration (years) 
 
26.2 (5.4) 25.8 (6.1) 26.1 (5.6) 23.3 (6.9)* 26.0 (5.7) 
Age at diabetes 
diagnoses 
 
10.2 (4.2) 10.0 (3.9) 10.1 (4.0) 10.6 (4.2) 10.1 (4.0) 
Year of diabetes 
diagnosis 
 
1971.8 (4.1) 1971.9 (4.2) 1971.8 (4.1) 1971.7 (4.2) 1971.8 (4.2) 
 
 
Year of diabetes diagnosis (N, % confirmed dead at follow-up) 
1965- 1969 
(n=428) 
 
 
62 (9.8%) 56 (8.9%) 101 (8.5%) 17 (22.1%) 118 (9.4%) 
1970- 1974 
(n=446) 
 
 
28 (4.4%) 30 (4.7%) 50 (4.2%) 8 (10.4%) 58 (4.6%) 
1975-1975 
(n=387) 
 
 
11 (1.7%) 13 (2.1%) 22 (1.9%) 2 (2.6%) 24 (1.9%) 
Total 
(n=1261) 
101 (16.0%) 99 (15.8%) 173 (14.6%) 27 (35.1%) 200 (15.9%) 
* Significant at p<0.05 
 
  44
 
5.1.2. Total (crude) mortality 
 
Overall, 200 deaths were observed (16.8 percent). Those dying were significantly (p<0.001) 
younger, had a shorter duration of diabetes, were older when they developed diabetes and 
their year of diagnosis was earlier (Table 2.). No difference was found by gender, however, 
African Americans had a greatly increased risk of death (hazard ratio= 3.3, 95% confidence 
interval: 2.2-5.0) compared to Caucasians. 
 
Table 2. Characteristics of patients by living status and year of diagnosis 
(The combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA registries) 
 
  Alive Died 1965-69 1970-74 1975-79 
n 983 200 427 447 387 
Living status confirmed (%) 983 (100) 200 (100) 398 (93.2) 423 (94.6) 362 (93.5) 
Males (%) 494 (50.3) 101 (50.5) 217 (50.8) 235 (52.6) 183 (47.3) 
African Americans (%) 38 (3.9) 27 (13.5)* 25 (5.9) 28 (6.3) 24 (6.2) 
mean (SD) shown      
Age (yrs) 36.9 (5.8) 32.3 (8.2)* 39.2 (6.9) 36.2 (5.9) 32.6 (4.7)* 
Diabetes duration (yrs) 27.0 (4.6) 21.0 (7.9)* 29.5 (6.2)  26.1 (4.5) 21.1 (3.2)* 
Age at onset (yrs) 9.8 (4.1) 11.3 (3.9)* 9.8 (4.3) 10.1 (3.9) 10.5 (3.9) 
Year at onset 1972.3 (4.1) 1969.4 (3.6)* 1967.1 (1.4) 1972.0 (1.4) 1976.8 (1.4)*
* Significant at p<0.001 
 
In the Cox regression models, age at onset, diagnosis year, and race predicted total mortality 
with the hazard ratios of 1.1 (95% CI=1.0-1.3), 0.90 (0.86-0.94), 3.3 (2.2-5.0), respectively 
(Table 3.).  
 
Table 3. Hazard ratios (95% CI) from Cox proportional models for all cause, acute 
complication and chronic complication mortality 
(The Combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA Registries) 
 
Variable All cause Mortality 
(95%CI) 
Acute Complications 
(95% CI) 
Chronic Complications 
(95%CI) 
Race 3.3 (2.2, 5.0) 4.9 (2.0, 11.7) 1.1 (.54, 2.0) 
Diagnosis year 0.90 (0.86, .94) 1.2 (1.0, 1.3) 1.2 (1.0, 1.4) 
Age at diabetes 
diagnosis 
1.1 (1.0, 1.3) .85 (0.76, 0.93) 1.1 (0.99, 1.3) 
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5.1.3. Causes of deaths 
 
Underlying and secondary causes of death were adjudicated for 82 percent (n=164) of the 
deceased cases, all of whom had a death certificate. In addition, hospital records (58 percent), 
coroner and autopsy reports (14 percent), and interview with the next of kin (12 percent) were 
available. Among the 164 deceased whose causes of death were verified, 19 percent (n=31) 
died from acute diabetes complications (24 diabetic ketoacidosis, five hypoglycemia, and two 
unspecified coma), 101 from chronic diabetes related complications (22 renal, 50 
cardiovascular, 27 infection and two unspecified diabetes related causes), 15 percent (25) died 
from other non-diabetes related causes (six from suicide, three from accident, two from drug 
abuse, six from cancer, two from post-transplant complication, six from other various causes). 
The cause of death could not be determined in seven cases. 
According to the proportionate analysis of cause-specific mortality, the leading cause of 
deaths was the group of cardiovascular diseases, mainly heart disease and coronary artery 
disease, followed by acute complications mainly diabetic ketoacidosis. Infection and renal 
disease played also a big role in the causes of death, while other causes involve diabetes and 
non-diabetes related problems, post-surgical complications, but mainly cancer (Figure 1a-b.).  
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Figure 1a-b. Proportionate cause-specific mortality by sex and race 
(The Combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA Registries) 
all numbers in percentage 
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*Significant at p<0.01 
RD=Renal Disease; AC=Acute Complication; AS=accident/suicide; CV=cardiovascular disease; ID=infection;  
OC=other causes (cancer, diabetes related, unrelated causes, postsurgical complications) 
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Similar pattern was seen in the cause-specific mortality rates per 100,000 person-years  
(Table 4.).  
 
Table 4. Cause-specific mortality rates per 100,000 person years (95% CI) 
The combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA registries 
 
 
Cause of death n=164 rate/100.000 person-years (95% CI) 
Renal disease 22 71.6 (55.0-88.2) 
Acute complication 31 100.9 (81.2-120.6) 
Accident/suicide/drug abuse 11 35.8 (24.1-47.5) 
Cardiovascular disease 50 162.7 (137.7-187.7) 
Infection 27 87.8 (69.4-106.2) 
Other causes 23 74.8 (57.8-91.7) 
 
 
 
5.1.4. Gender differences 
 
There was no difference by gender seen in terms of the acute and various chronic 
complications (Figure 1a.) in the proportionate analysis of causes, however, significantly 
more deaths from accident/suicide were seen among males (p<0.01). 
To make more exact analysis about mortality differences by sex and race, twenty-year cause-
specific mortality rates per 100,000 person years were calculated for acute, chronic diabetes 
complications, non-diabetes related and unknown causes (Table 5.) Although confidence 
intervals overlap, males had a somewhat higher mortality from non-diabetes related causes 
(especially accident/suicide) than females. No other gender differences were seen in cause-
specific mortality which is unrelated to race. 
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Table 5. Twenty-year cause-specific mortality rates (n and %) per 100,000 person years (95% CI) by sex and race 
(The Combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA Registries) 
 
 
 
Gender 
 
Race 
Cause of death 
N Overall rate 
 
Male  Female  Caucasian  African American 
       
Acute complications 
 
 
31 100.7 (65.3, 136.1) 96.0 (47.4,144.6) 
 (n=15) 
105.4 (53.8, 157)  
(n=16) 
75.2 (43.8, 106.6) 
(n=22) 
593.2 (205.6, 980.8) 
(n=9) 
Chronic 
complications 
 
 
101 328.2 (264.2, 392.2) 307.5 (220.6, 394.4) 
(n=48) 
349.4 (255.4, 443.4) 
(n=53)  
311.2 (247.3, 375.1) 
(n=91) 
659.1 (250.6, 1067.6) 
(n=10) 
Non diabetes  
related causes 
 
 
25 81.2 (49.4, 113.1) 115.3 (62.1, 168.5)  
 (n=18) 
46.1 (12, 80.2)  
(n=7) 
85.5 (52.1, 119.2) 
(n=25) 
0 
Unknown causes 
 
 
7 22.7 (5.9, 39.5) 19.2 (-2.5, 40.9) 
 (n=3) 
26.3 (0.5, 52.1)  
(n=4) 
20.5 (4.1, 36.9) 
(n=6) 
65.9 (-63.3, 195.1) 
(n=1) 
Total deceased 164 532.9 (451.4, 614.4) 538.2 (423.1, 653.3)  
(n=84) 
527.4 (411.8, 643.0) 
(n=80) 
492.1 (412.1, 572.9) 
(n=144) 
1318.4 (1168, 1468.8) 
(n=20) 
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5.1.5. Racial differences 
 
The racial distribution of the proportionate mortality approach (Figure 1b.) showed a 
dramatic significant difference between African-Americans and Caucasians in the proportion 
of acute diabetes complications (45% vs. 15%, respectively). 
Same pattern was revealed from the twenty-year mortality analysis. African Americans had a 
higher mortality from acute complications (mainly ketoacidotic coma) compared to 
Caucasians (Table 5.). The increased mortality from acute complications in African 
Americans was apparent in both genders though only significant in women, e.g. for women 
the rate for mortality from acute complications in African Americans was 13 percent 
compared to 1.2 percent in Caucasians, while for men the difference was 10 percent vs 2.0 
percent (Table 6.). Racial difference was further examined; no difference was seen by age or 
duration while the major underlying cause of death from acute complications was diabetic 
ketoacidosis in both races. The rates regarding the other diabetes-related and non-related 
causes did not differ significantly between the racial groups. 
The proportion of patients whose causes of death were determined based on death certificate 
alone was somewhat higher among African Americans compared to Caucasians (22 percent 
vs 12 percent, respectively, p<0.05). 
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Table 6.  Twenty-year acute and chronic complication mortality rates (per 100,00 person years and 95%CI) by racial groups 
(The Combined Children’s Hospital of Pittsburgh and the Allegheny County, PA registries) 
 
 Caucasian 
 
 
African American 
Cause of death 
 
Male  Female  Male Female 
     
Acute complications 
 
 
12 80.1 (34.8, 125.4) 10 70.1 (26.7, 113.5) 3 477.7 (-46.8, 1018.2) 6 674.9 (134.9, 1214.9)  
Chronic complications 
 
 
44 293.7 (207, 380.4) 47 329.6(320.2, 423.8) 4 636.9 (12.7, 1261.1) 6 674.9 (134.9, 1214.9) 
Total deceased 
 
56 373.8 (280.9, 476.7)   57 399.7 (296, 503.4) 7 1114.6 (288.3, 9371) 12 1349.8 (586.1, 2113.5) 
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The cumulative hazard curve for acute complication death was significantly worse in African 
Americans, started separating from the hazard curve of Caucasians already after 10 year of 
diabetes duration (Figure 2.). No difference was seen, however, in the chronic complication 
hazard curves between the two races. 
 
Figure 2a-b Cumulative hazard for complication deaths by race.  
(The Combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA Registries) 
Figure 2/a: Cumulative hazard for acute complication death by race
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Figure 2/b: Cumulative hazard for chronic diabetes complication death by race
Log rank p=0.67
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In the Cox regression models, race, age at onset, and diagnosis year predicted total mortality 
(Table 7.). Race and age at diabetes diagnosis were independently predictive for mortality 
from acute complications, while for mortality from chronic complications, only diagnosis 
year was predictive (hazard ratio= 1.2: 95% confidence interval: 1.0, 1.4). 
 
Table 7. Hazard ratios (95% CI) from Cox proportional models for all cause, acute 
complication and chronic complication mortality 
(The Combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA Registries) 
 
Variable All cause Mortality 
(95%CI) 
 
Acute 
Complications 
(95% CI) 
Chronic Complications 
(95%CI) 
Race 
 
3.3 (2.2, 5.0) 4.9 (2.0, 11.7) 1.1 (.54, 2.0) 
Diagnosis year 
 
0.90 (0.86, .94) 1.2 (1.0, 1.3) 1.2 (1.0, 1.4) 
Age at diabetes 
diagnosis 
1.1 (1.0, 1.3) .85 (0.76, 0.93) 1.1 (0.99, 1.3) 
 
 
5.1.6. Temporal trends in cause specific mortality 
 
For analyzing any potential temporal trends in mortality, twenty-year cause specific mortality 
rates were examined by diagnosis cohort (Table 8). Major, significant declines were seen both 
overall, and for chronic complications alone. Though less marked (i.e. confidence intervals 
overlap) probably due to lower number of events, acute complications and non-diabetes 
related causes also showed a similar decline. Though a decreasing trend was apparent for both 
Caucasians and African Americans for each cause, only the decline in chronic complication 
mortality rates among Caucasians reached the level of significance reflecting, at least in part, 
the smaller sample size for African Americans.  
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Table 8. Temporal trends in 20-year cause specific mortality rates (per 100,000 and 95% CI) 
(The Combined Children’s Hospital of Pittsburgh, PA and the Allegheny County, PA Registries) 
 
Year of diabetes diagnosis 
 
 
 1965-1969 
 
 
1970-1974 1975-1979 
Cause of death 
 
 
Number Rate (95%CI) Number Rate (95%CI) Number Rate (95%CI) 
       
Acute complications 
 
 
15 127.8 (63.2, 192.4) 12 108.8 (51, 166.6) 4 50 (1, 99) 
Chronic complications 
 
 
61 519.7 (389.3, 650.1) 29 262.9 (173, 352.8) 11 137.7 (56.4, 219) 
Non diabetes related causes 
 
 
16 136.3 (69.8, 203.1) 6 54.4 (13.5, 95.3) 3 37.5 (-5, 80) 
Unknown causes 
 
 
4 34.0 (0.6, 67.4) 1 9.1 (- 7.6, 25.8) 2 25 (-9.7, 59.7) 
Total 
 
 
96 817.9 (654.3, 981.5) 48 435.3 (312.2, 558.4) 20 250.4 (140.7, 360.1) 
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5.2. Differences in mortality between Havana and Allegheny County 
 
5.2.1. Living status and demographic characteristics 
 
Overall 887 individuals from the Allegheny County cohort (AC) and 504 individuals from the 
Havana city cohort (HA) with childhood onset T1D met the criteria for inclusion and 
therefore were included in the study. The living status of 852 (ascertainment rate of 96.1%) 
from the AC cohort and 470 (ascertainment rate of 93.3%) from the HA cohort was 
established as of 1 January, 1991. (Table 9.). No differences between registries were seen in 
men, although women in HA were less likely to have their vital status determined (92% vs. 
97%., p<0.05). 
 
Table 9. Demographic Characteristics of Studied Population  
(US: Allegheny County, PA Registry, 1965-1979 and Cuba: Havana Registry, 1965-1980). 
 
Males Females  
Allegheny County Havana Allegheny County Havana 
N 449 259 438 245 
Living Status Confirmed 428 (95.3) 244 (94.2) 424 (96.8)* 226 (92.3)* 
Age at Onset 9.2 (3.7) 8.8 (3.8) 9.3 (3.4) 8.3 (3.7) 
Year of Onset 1971.7 (3.9) 1973.4 (4.4) 1971. 7 (4.1) 1973.1 (4.6) 
Mean DM Duration 18.8 (4.3) 16.5 (4.8) 18.6 (4.7) 16.5 (5.0) 
Person-years 8,456 4,237 8,156 3,996 
*HA vs. AC significant at p<0.05 
 
 
5.2.2. Mortality rates and standardized mortality ratios 
 
Cumulative survival by registry demonstrated a worse survival in HA (84% at 20 years) than 
AC (91% at 20 years) (Figure 3.).  
Mortality in HA was higher than in the AC in both genders (males, p<0.01; females, p=0.05).  
Mortality rates were higher in HA for both men and women although in women confidence 
intervals overlapped. SMR were significantly higher in HA in both sexes.  
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Figure 3. Cumulative survival of subjects by registry 
(US: Allegheny County, PA Registry, 1965-1979 and Cuba: Havana Registry, 1965-1980). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC: Allegheny County registry; HA: Havana City Registry 
 
 
5.2.3. Causes of deaths 
 
When underlying causes of deaths (Table 10) were examined, major differences in cause 
specific mortality were found. More deaths in AC were attributed to acute complications than 
to any other cause, while in HA the leading cause of death was nephropathy, which accounted 
for nearly half of the deaths. Interestingly the mortality rate for acute complications was lower 
in HA than in AC (although this difference was not significant) while renal mortality was 
eight times higher in HA than in AC (430/100,000 vs. 53 /100,000 person-years). There was 
an excess mortality among African-Americans attributed to acute complications 
(406/100,000) and infections (271/100,000) when compared to the Hispanics of HA or the 
Caucasians of AC.  
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Table 10. Cause specific mortality rate (x 100,000 person-years) by country and race. 
(US: AC, PA Registry, 1965-1979 and Cuba: HA Registry, 1965-1980). 
 
 
Allegheny County Cuba 
Caucasians African-Americans Total Hispanics 
 
Causes of Death 
Rate % Rate % Rate % Rate % 
Nephropathy 44 12.5 172 18.2 53 13.4 430 48.6 
95%-CI 21-108  37-1,765  28-113  313-608  
Acute Complications 108 25.0 406 36.4 128 26.9 66 7.1 
95%-CI 63-193  150-1,473  82-213  28-196  
CVD 73 19.6 - - 67.7 16.4 130 14.3 
95%-CI 41-143  -  38-133  72-262  
Infections 65 17.9 271 27.3 79 19.4 136 14.3 
95%-CI 35-135  86-1,297  46-147  75-276  
Other 87 21.4 - - 81 17.9 149 16.0 
95%-CI 50-164  -  46-152  85-289  
Unknown 13 3.6 172 18.2 24 6.0 - - 
95%-CI 3-141  36-1,799  9-88    
Total 390. 100.0 1,022 100.0 434 100.0 911 100.0 
95%-CI 302.1-512.2  591-1,919  344-556  733-1,147  
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5.2.4. Gender differences 
 
Gender differences were not seen in the demographic characteristics of each cohort, nor in the 
mortality rates and standardized mortality ratios (Table 11.).  
 
Table 11. Age-Sex-Adjusted Mortality Rate and Standardized Mortality Ratios by Gender  
(US: AC, PA Registry, 1965-1979 and Cuba: HA Registry, 1965-1980). 
 
Males Females  
AC HA AC HA 
N 449 259 438 245 
Deceased (%)1 29 (7) 37 (14) 38 (9) 33 (14) 
Mortality Rates X 
100,000 
368 925 503 897 
95%-CI 259-539 687-1,275 369-703 655-1,262 
SMR  342 858 378 882 
95%-CI 236- 513 618-1,228 
 
266-556 
 
670-1,274 
1 AC vs. HA p< 0.01 for males; p=0.05 for females; Caucasians vs. African Americans p<0.01; African 
American vs. Hispanics p=0.44. 
 
 
Based on the Cox proportional hazard model (Table 12.), the risk of death was not associated 
to gender (OR=1.1, 95% CI: 0.8-1.5, p=0.668). 
 
Table 12. Cox Proportional Hazard Model for all cause mortality. 
(US: AC, PA Registry, 1965-1979 and Cuba: HA Registry, 1965-1980). 
 
Factor OR 95%-CI p 
Sex, Male:Female 1.1 0.8-1.5 0.668 
Race, US Caucasians:US African Americans 2.8 1.5-5.4 0.002 
Race, US Caucasians:Cuban Hispanics 3.3 2.2-5.0 <0.001 
Year of Diagnosis 1.1 0.8-1.3 0.548 
Year of Birth 0.9 0.9-0.6 0.435 
Age at Diagnosis 0.9 0.6-1.4 0.652 
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5.2.5. Racial differences 
 
The cumulative survival analysis of subjects by race (Figure 4.) suggests that mortality in AC 
for African-Americans was worse than for Caucasians but similar to that seen in HA for 
Hispanics.  
 
Figure 4. Cumulative survival of subjects by race 
(US: Allegheny County, PA Registry, 1965-1979 and Cuba: Havana Registry, 1965-1980). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Same pattern was seen when adjusted mortality rates and SMRs were analyzed (Table 13.).  
 
Table 13. Age-Sex-Adjusted Mortality Rate and Standardized Mortality Ratios by Race  
(US: AC, PA Registry, 1965-1979 and Cuba: HA Registry, 1965-1980). 
 
 Race 
AC HA  
Caucasian African-American Hispanic 
N 823 63 504 
Deceased (%)* 56 (7) 11 (18) 70 (14) 
Mortality Rates x 100,000 390 1,022 912 
95%-CI 302-512 591-1,919 733-1,147 
SMR  285 922 840 
95%-CI 215-385 515-1,820 665-1,077 
*Caucasians vs. African Americans p<0.01; African American vs. Hispanics p=0.44. 
Figure 3. Cumulative Survival by Ethnicity.
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Results of the Cox proportional hazard model for all cause mortality indicated that after 
adjusting for age, gender, year and age of diagnosis the Odds Ratio was 3.3 (95%-CI=2.2-5.0, 
p<0.001) times higher for Hispanics than for Caucasians (Table 12.). For African-Americans 
the risk of any cause mortality was 2.8 (95%-CI=1.5-5.4, p=0.002) times higher compared to 
Caucasians. The risk of death was not associated with sex, year of diagnosis, year of birth or 
age at diagnosis, after controlling for ethnic group. 
 
5.2.6. Effect of age at onset and year of diagnosis 
 
Mortality in HA was higher irrespective of age at diagnosis (Table 14.) though this was not 
statistically significant among those with onset 0-4 years of age (p=0.08 for 0–4 years; p<0.01 
for 5–9 years; p<0.01 for 10–14 years). The difference in crude mortality and SMR between 
the Havana and Allegheny County cohort became even more dramatic in the 1970s (p=0.28 
for 1965–1970; p<0.01 for 1971–1980.), however, a nice decreasing trend in the standardized 
mortality ratios could be seen in both cohorts with the later years of diagnosis. 
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Table 14. Mortality Rates and Standardized Mortality Ratios by Age at Diabetes Onset and Diabetes Diagnosis  
(US: Allegheny County, PA Registry, 1965-1979 and Cuba: Havana Registry, 1965-1980). 
 
 Age at Diagnosis Year of Diagnosis 
 0-4 5-9 10-14 65-70 71-80 
 AC HA AC HA AC HA AC HA AC HA 
N 105 95 306 178 476 231 367 148 520 356 
Deceased* (%) 5 (5) 11 (12) 17 (6) 25 (14) 45 (9) 34 (15) 45 (12) 32 (22) 22 (4) 38 (10) 
Mean Survival 
Time 
25.2 24.5 25.2 23.7 24.6 23.3 24.9 23.9 19.5 18.9 
95%-CI 24.5-
26.0 
23.6-25.3 24.8-25.5 22.9-24.5 24.2-25.0 22.4-24.1 24.5-25.2 23.2-24.6 19.3-19.7 18.6-19.3 
Crude 258 679 328 886 562 1,056 594 1,162 295 777 
95%-CI 109-765 395-1,271 208-548 618-1,315 425-761 755-1,477 449-901 851-1,626 197-464 577-1,072 
SMR 149 612 263 901 492 980 547 1,141 185 715 
95%-CI 46-740 
 
336-1,239 
 
158-472 
 
615-1,374 
 
362-685 695-1,427 
 
408-752 814-1,649 111-333 515-1,022 
 
Background mortality for Standardized Mortality Ratios calculation: general US population for Allegheny County and the Cuba general 
population for Havana. 
*AC vs. HA: p = 0.08 for 0–4 years; p < 0.01 for 5–9 years; p < 0.01 for 10–14 years; p = 0.28 for 1965–1970; p < 0.01 for 1971–1980. 
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5.3. Incidence of coronary artery disease (CAD) and nephropathy (MA, ON, ESRD) 
 
5.3.1. DERI complication survey 
 
Out of the 1075 individuals who comprised the Allegheny County registry (DERI-USA 
cohort), living status of 975 (91 %) and complication status of 788 (73%) for CAD and 798 
(74%) for ESRD was ascertained as of 1 January 1999. There was no statistically significant 
differences in frequencies by year of onset (p=0.16) or sex (p=0.70) between those traced and 
those missing on 1 January, 1999, however, mean age at onset was higher (11.5±4.2 (±SD) 
year vs. 10.7±4.1 year, p=0.003) and the proportion of Caucasians was lower (88 vs. 94%, 
p=0.007) in those not traced. 
 
Coronary artery disease: 
During the observational period, 63 (8%) subjects developed CAD. Mean age at diabetes 
onset was 10.4±4.2 (±SD) while mean diabetes duration at death from CAD or censoring was 
24.9±5.8 years. Incidence density was calculated as 325/100,000 person-years. Cumulative 
incidence rate of CAD was determined as 9.1% at 25 years, while other rates were 0.7% at 15; 
3.0% at 20; and 28.1% at 30 years, respectively. No differences by gender or race were seen 
in the incidence rates (Figure 5a-b.). 
 
Figure 5a. Cumulative incidence rate of CAD by gender 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
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Figure 5b. Cumulative incidence rate of CAD by race 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
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When sub-cohorts by year of diabetes onset (1965-69, 1970-74 and 1975-79) were compared, 
the mean age at onset (11.5± 5.6 yrs) for subjects diagnosed between 1975-79 was 
significantly (p=0.01) higher than for those diagnosed between 1965-69 (10.6±4.4 yrs) and 
1970-74 (10.7±4.1 yrs), however, differences were not seen in sex and race. The cumulative 
incidences of CAD were not different significantly between patients diagnosed in earlier 
calendar years and those diagnosed more recently (Table 15.). 
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Table 15. Cumulative incidence rates of coronary artery disease (CAD) by the year of 
diabetes diagnosis 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
 
 
 1965-69 1970-74 1975-79 
 CAD (n) 
Incidence 
rate (%) CAD (n) 
Incidence 
rate (%) CAD (n) 
Incidence 
rate (%) 
at 20 yrs 6 3,0% 7 2,8% 7 3,1% 
at 25 yrs 15 7,6% 16 6,9% 9  
at 30 yrs 24 14,1% 24  9  
 
 
 
 
End-stage renal disease: 
During the observation, 104 individuals (13.0%) developed ESRD. Mean duration of diabetes 
at death or censoring was 25.0±5.6 (±SD) years. The incidence rate of ESRD was 
521/100,000 person-years. Cumulative incidence rate of ESRD was 11.3 % at 25 year of 
diabetes (Figure 6a.). The 20-year cumulative incidence rates of ESRD for the subjects 
diagnosed between 1965-69, 1970-74 and 1975-79 were 9.1%, 4.7% and 3.6% respectively, 
and differences between 1965-69 vs. 1970-74 (p=0.0073) and 1965-69 vs. 1975-79 
(p=0.0091) were statistically significant (p value for 3 survival curves=0.006) (Figure 6c.). 
The 20-year cumulative incidence rate of ESRD in African Americans was statistically higher 
than that of Caucasians (21.9% vs. 5.2%: p<0.0001) (Figure 6b). 
 
Figure 6a-c. Cumulative incident rates (n/100) of end-stage renal disease (ESRD) 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
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A: overall,  
B: Caucasian (1) vs. African-American (2) (p<0.0001),  
C: diagnosed between 1965-69 (1), 1970-74 (2) and 1975-79 (3) (p=0.006) 
 
Cox proportional modeling indicated that a lower age at onset (OR=0.90/year, 95% CI: 0.85-
0.95, p=0.001), a diagnosis in recent years (OR=0.55 (1970-74 vs. 1965-69), 95% CI: 0.34-
0.88, p=0.013, and OR=0.39 (1975-79 vs. 1965-69), 95% CI: 0.20-0.74, p=0.0041) and being 
Caucasian (OR=0.60 (Caucasian vs. African-American), 95% CI: 0.46-0.77, p<0.0001) were 
protective against ESRD. 
 
5.3.2. EDC complication follow-up 
 
After excluding baseline cases (n=53) and those with no follow-up (n=19), 15% (56/382) of 
individuals developed new onset coronary artery disease (CAD) during the 6-year follow-up 
(see baseline characteristics in Table 16.). Similarly, 29 incident cases (10%) of overt 
nephropathy (ON) were diagnosed out of 294 eligible subjects. During complication follow-
up with a total of 2113 person-years for CAD and 1620 person-years for ON, somewhat 
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higher incidence density was seen for CAD than ON (24.6/1000 person-years vs. 17.3/1000 
person-years). 
 
5.3.3. University of Pecs, albuminuria follow-up 
 
5- and 10-year cross-sectional results of 107 patients with childhood (<18 years) onset Type 1 
diabetes were examined. Mean age at onset of the 44 boys and 63 girls was 6.4±3.9 (±SD) 
years. 88 children (35 boys and 53 girls) examined on the 5-year follow-up visit while only 44 
(18 boys and 26 girls) could be reached at 10 years for the hospital follow-up. 
Results showed a microalbuminuria (MA) incidence of 18 percent (n=19/107) at 5 years of 
diabetes duration, however, 39% of subjects developed median-albuminuria (≥14.5mg/day). 
The 10-year cumulative incidence rate of MA was found to be 23% (10/44). There was no 
difference seen in gender regarding the incidence rates at 5 and 10 years.  
The 5-year incidence of MA was found to be significantly lower (chi square trend p<0.01) 
among patients with early childhood (0-4 years) onset T1D compared to those in higher age 
groups (5-9, 10-17 yrs) by diabetes onset (Figure 7).  
In the 5-year longitudinal analysis, progression from normoalbuminuria to MA was revealed 
in 30% of patients, while improvement from MA to normoalbuminuria was detected only in 
two cases (7.4%). 
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Figure 7. Cumulative incidence of MA at 5 and 10 years by age at diabetes onset 
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5.4. Risk factors and predictors of coronary artery disease (CAD) and nephropathy (MA, 
ON) 
 
5.4.1. EDC complication follow-up 
 
Baseline risk factors by CAD and ON incidence status at 6-year follow-up were analyzed 
(Table 16.). 
Compared to participants who remained free of CAD, those who developed the disease had 
significantly higher age, duration, HbA1, total and LDL cholesterol, triglycerides, systolic 
blood pressure, Beck depression score, white blood cell count (WBC), fibrinogen and lower 
estimated glucose disposal rate (eGDR - a good estimation of insulin sensitivity). 
HbA1 and triglycerides were statistically higher in incident cases of ON compared to non-
cases, although again, eGDR was lower in those who developed overt nephropathy. 
Significantly more hypertensive individuals were found among both CAD and ON cases then 
in those did not develop the complications. However, the number of smokers was 
significantly higher only among ON cases compared to non-cases. Among the components of 
the fibrinolytic system, PAI-1 values were lower while tPA-PAI-1 values were higher in 
incident CAD compared to the non-cases, though the trends were non-significant. However, 
after adjustment for age, PAI-1 correlated positively (r=0.02) with CAD status. For incident 
ON, both PAI-1 and tPA-PAI-1 were higher in those who developed the complication, 
although only the latter difference was significant. This association became somewhat 
stronger (p=0.02) when only those were analyzed who did not develop CAD simultaneously. 
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Table 16. Baseline risk factors and markers by complication incidence status 
(Pittsburgh Epidemiology of Diabetes Complications Study: 6-yr follow-up (1990-1992 to 1996-1998)) 
 
WHR: waist to hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cell count; eGDR: estimated Glucose Disposal Rate; HTN: 
hypertension 
 
 
  CAD 
(n=56) 
Non-CAD 
(n=326) 
P-value ON 
(n=29)  
Non-ON  
(n=265) 
P-value 
Age (yrs) 36.1±7.1 30.1±7.4 <0.001 31.5±6.7 31.1±8.1 0.74 
Duration (yrs) 28.4±7.3 21.5±6.9 <0.001 21.5±7.7 22.7±7.6 0.43 
BMI (kg/m2) 24.5±3.6 24.2±3.2 0.52 23.4±3.2 24.4±3.2 0.13 
WHR* 0.83±0.07 0.81±0.07 0.08 0.82±0.07 0.81±0.07 0.48 
HbA1 (%) 11.2±1.6 10.7±1.7 0.03 11.7±2.0 10.5±1.5 0.008 
Cholesterol (mmol/L) 5.34±1.0 4.71±1.1 <0.001 5.08±1.2 4.66±0.8 0.07 
HDL-chol (mmol/L) 1.30±0.3 1.37±0.3 0.17 1.34±0.3 1.34±0.3 0.87 
LDL-chol (mmol/L) 3.32±0.8 2.90±0.9 0.001 3.10±0.9 2.85±0.7 0.16 
TG (mmol/L) 1.45±0.9 1.00±0.7 <0.001† 1.32±0.9 0.97±0.6 0.04† 
SBP (mmHg) 122±16 112±14 <0.001 110±14 111±12 0.87 
DBP (mmHg) 74±12 71±9 0.09 73±8 70±8 0.10 
Beck score 8.4±7.7 5.3±5.3 0.006‡ 8.0±7.5 5.5±5.8 0.06‡ 
WBC (x109/L) 7.6±1.9 6.9±2.1 0.01† 7.1±1.7 6.9±2.1 0.43† 
eGDR (mg/kg/min) 6.6±2.3 7.8 ±1.7 0.001 6.2±2.1 8.1±1.5 <0.001 
HTN (%) 34 12 <0.001 31 7 <0.001 
Smoking (%) 22 15 0.24 28 13 0.05 
Fibrinogen (mg/dL) 327 ±86 291 ±96 0.006 340 ±147 284 ±90 0.06 
PAI-1 (ng/mL) 23.8±16.9 26.1±17.3 0.39† 28.3±17.9 25.3±17.0 0.45† 
tPA-PAI-1 (ng/mL) 1.48±0.7 1.40±1.0 0.38† 1.68±0.8 1.41±1.0 0.04† 
 
* determined two years earlier; † log transformed before testing; ‡ non-parametric test performed 
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The incidence densities of CAD and ON by PAI-1 levels did not reveal any significant trend 
for either measure. However, a significant trend (p<0.01) for an increased incidence of ON by 
tPA-PAI-1 tertiles was seen (Figure 8.). 
 
Figure 8. Incidence density of overt nephropathy by plasminogen activator inhibitor-1 (PAI-1) and 
tissue plasminogen activator (tPA)-PAI-1 levels. 
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significant trend (p<0.01) by tPA-PAI-1 tertiles 
 
 
No difference was seen in the trends between males and females. A significant decreasing 
trend in incidence of both CAD and ON by eGDR tertiles was observed (p<0.01) showing 
univariate association between the complications and insulin resistance (Figure 9.). 
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Figure 9. Incidence density of coronary artery disease (CAD) and overt nephropathy (ON) by tertiles 
of estimated glucose disposal rate (eGDR - an estimation of insulin resistance) 
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significant trend (p<0.01) for CAD and ON by eGDR tertiles 
 
In Cox regression models the following variables were available for modeling: age, HbA1, 
triglycerides, hypertension, Beck score, WBC, eGDR, fibrinogen, PAI-1 and tPA-PAI-1. In 
the Cox model only age (RR=1.05, 95% CI: 1.0-1.2, p=0.025) and triglycerides (RR: 14.2, CI: 
1.5-22.2, p<0.001) were independent predictors of CAD while in the case of ON, HbA1 (RR: 
1.4, CI: 1.1-1.9, p=0.022) and eGDR (RR: 0.7, CI: 0.3-0.9, p=0.001) predicted the 
development of complication. 
 
5.4.2. University of Pecs, albuminuria follow-up 
 
5- and 10-year cross-sectional and 5-year longitudinal follow-up results of 107 children with 
Type 1 diabetes were examined. 
5-year cross-sectional data showed significant correlation between albuminuria and age 
(r=0.23, p<0.05). Patients with MA were significantly older (Table 17.) and they had 
significantly higher Tanner-score (p<0.01).  
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Table 17. Characteristics of patients at 5 years of diabetes duration by albuminuria status 
8.9±1.4
4.4±0.9
0.9±0.2
0.9±0.7
4.5±0.8
69.2±12.1
105.7±15.1
20.0±4.7
2.5±1.6
11.0±3.8
66
Normoalbuminuria
0.688.7±1.9HbA1c (%)
0.554.5±0.8Insulin shots (n/day)
0.810.9±0.3Insulin/kgbw (U/kg)
<0.013.7±1.4Tanner-score
0.630.9±0.5Triglyceride (mmol/l)
0.804.5±0.9Cholesterol (mmol/l)
0.7220.6±6.6BMI (kg/m2)
0.8869.7±11.6Diastolic blood pressure (mmHg)
0.00114.6±3.6Age (years)
0.38109.8±18.0Systolic blood pressure (mmHg)
19N
p-valueMicroalbuminuria
mean ± SD
 
 
Beyond the above differences, those with median-albuminuria had significantly higher BMI 
and systolic blood pressure values (p<0.02) compared to the normoalbuminuric children. 
Individuals with higher Tanner-score (=4-5; more mature during puberty) had an almost 3-
fold bigger chance (OR=2.7, 95% CI: 1.0-7.8, p=0.05) for developing MA than children with 
lower maturity degree (Tanner-score: 1-3). 
In multivariate analysis only age was proved to be an independent predictor of MA or 
median-albuminuria (RR=1.4, 95% CI: 1.1-1.8; RR=1.4, 1.1-1.7, respectively).  
Significantly higher HbA1c (p<0.01), systolic blood pressure (p<0.001), insulin requirement 
(p=0.01) and Tanner-score (p<0.001) was found at 10 years compared to the previous visit at 
5 years. Markedly higher HbA1c, systolic blood pressure, insulin requirement and Tanner-
score was detected in subjects with progression from normoalbuminuria to MA, however, the 
differences were not statistically significant (Table 18.). The mean Tanner-score was found to 
be significantly higher (p<0.05) among children with an albuminuria progression of 
14.5mg/day during the 5-year follow-up. 
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Table 18. Characteristics of patients by 5-year progression to microalbuminuria 
(incident cases: progression to MA between the 5-yr and 10-yr visit) 
9.9±1.2
4.5±0.6
0.9±0.2
1.1±0.5
4.6±0.9
72.4±10.9
118.2±12.3
21.5±3.1
3.7±1.6
15.5±3.2
19
Non-cases
10.4±2.3HbA1c (%)
4.6±0.5Insulin shots (n/day)
1.1±0.3Insulin/kgbw (U/kg)
4.4±0.9Tanner-score
0.9±0.4Triglyceride (mmol/l)
4.5±0.8Cholesterol (mmol/l)
21.3±2.5BMI (kg/m2)
71.1±8.2Diastolic blood pressure (mmHg)
15.2±2.8Age (years)
122.1±14.8Systolic blood pressure (mmHg)
8N
Incident cases
Non-significant differences (p>0.05)
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5.5. Survival after coronary artery disease (CAD) and revascularization (RV) therapy 
 
Among those patients who developed CAD in the DERI-USA, Allegheny County cohort (see 
section 5.3.1.) 35 subjects developed non-fatal myocardial infarction (MI), 41 underwent 
some form of revascularization (percutan transluminary coronary angioplasty (PTCA) in 20 
cases, coronary artery bypass grafting (CABG) in 12 cases and 9 patients underwent both) 
and 8 individuals died from CAD. The incidence rates of non-fatal MI and revascularization 
increased dramatically after 25-year of diabetes duration, while the incidence of fatal MI 
remained significantly lower compared to non-fatal MI (Figure 10). 
 
Figure 10. Cumulative incidence rate of coronary artery disease by its clinical manifestation 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
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MI: myocardial infarction 
Revascularization: percutan transluminary coronary angioplasty and/or coronary artery bypass grafting 
 
Cumulative survival of subjects with myocardial infarction followed by revascularization was 
76% at 5 years, (75%, in cases treated by PTCA only, 87.5%, with CABG and 60% of those 
underwent both forms of RV) (Table 19.). However, significantly less (p<0.01), only 53% of 
patients who developed MI but not treated with any form of revascularization survived 5 
years. Patients who underwent PTCA or CABG alone, regardless whether they developed 
myocardial infarction, had a significantly higher survival rate compared to those who 
developed MI but did not have any form of RV (p=0.003, p=0.04, respectively). 
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Table 19. 5-year cumulative survival of CAD by revascularization therapy 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
 
 No. of cases No. of deaths death rate (%) 5-year survival rate 
no MI, no RV 725 76 10,5%  
MI without RV 19 10 52,6% 52,6% 
MI followed by PTCA 8 2 25,0% 75,0% 
MI followed by CABG 8 2 25,0% 87,5% 
MI followed by PTCA+CABG 5 4 80,0% 60,0% 
     
PTCA without MI 16 2 12,5% 100,0% 
CABG without MI 7 1 14,3% 100,0% 
Any RV without MI 20 2 10,0% 100,0% 
 
MI: myocardial infarction; RV: revascularization therapy; PTCA: percutan transluminary 
coronary angioplasty 
CABG: cononary artery bypass grafting 
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5.6. Survival after end-stage renal disease (ESRD) and renal replacement therapy (RRT) 
 
Among those individuals who developed ESRD (n=104) in the DERI-USA, Allegheny 
County cohort (see section 5.3.1.), 29 patients (28%) received dialysis alone, 44 patients 
(42%) underwent dialysis followed by kidney transplantation, 26 (25%) underwent successful 
transplantation alone and 5 individuals (5%) had a failed kidney transplantation followed by 
dialysis therapy. In the group with dialysis therapy followed by kidney transplantation, mean 
duration between introduction of dialysis and transplantation was 1.5±1.6 (±SD) years. Of 
75 renal transplant recipients, information from 60 patients was available, as was whether 
they received pancreatic-kidney transplantation. Nineteen subjects underwent pancreatic-
kidney transplantation.  
Cumulative survival rates after introduction of RRT were 66.5% at 5 years and 51.2% at 10 
years, respectively (Figure 11a.). 
The 5-year cumulative survival rates after introduction of RRT of the subjects diagnosed 
between 1965-69, 1970-74 and 1975-79 were 58.8%, 73.5% and 87.5% respectively (Figure 
11b), however, the differences did not reach significance (p=0.07). 
Cumulative survival rates at 5 years by groups of dialysis therapy alone, dialysis followed by 
kidney transplantation, successful transplantation alone and failed kidney transplantation 
followed by dialysis therapy were 32.8 %, 85.8%, 62.0% and 80% respectively (Figure 11d.). 
The difference between dialysis therapy alone and dialysis followed by kidney transplantation 
reached significance (p<0.0001 and for 4 survival curves, p=0.0002). Cumulative survival 
rate of all transplant recipient was 79.6% at 5 year, which was significantly higher than that of 
the subjects of dialysis therapy alone (32.8%, p=0.0002) (Figure 11e). Survival of pancreatic-
kidney transplantation recipients initially tended to be worse, but was subsequently better, 
although the overall difference did not reach significance (p=0.7) (Figure 11f). 
Cox modeling revealed that the relative risk of death for all transplantation recipients against 
dialysis therapy alone was 0.25 (95% CI: 0.13-0.47; p<0.001). Among groups of dialysis 
followed by kidney transplantation, successful transplantation alone and failed kidney 
transplantation followed by dialysis therapy, only dialysis followed by kidney transplantation 
had significantly lower risk of death compared to dialysis therapy alone. In all transplant 
recipients, the relative risk of death for pancreatic-kidney transplantation recipients compared 
to those with kidney transplantation only was 0.51 (95% CI: 0.14-1.8; p=0.29).  
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Figure 11a-f. Cumulative survival rates after introduction of Renal Replacement therapy (RRT) 
(DERI-USA complication survey: Allegheny County, PA Registry, 1965-1979) 
 
 
 
 
A: overall 
B: diagnosed between 1965-69 (1), 1970-74 (2) and 1975-79 (3) (P=0.073) 
C: Caucasian (1) vs. African-American (2) (P=0.8) 
D: dialysis alone (DA: 1), dialysis followed by kidney transplantation (DK: 2),  
     successful transplantation alone (TA: 3), failed kidney transplantation followed by dialysis (KD: 4) 
     (DA vs. DK: p<0.0001, overall: p=0.0002) 
E: all transplantation recipient (1) vs. dialysis only (2) (P=0.0002) 
F: kidney transplantation (1) vs.pancreatic kidney transplantation (2) (P=0.7) 
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6. Discussion 
 
6.1. Cause-specific mortality rates in the Pittsburgh Metropolitan Area 
 
Our data are based on a combined analysis of both population (Allegheny County, 
Pennsylvania) and hospital (Children’s Hospital of Pittsburgh) based registries of childhood 
onset Type 1 diabetes. The majority of patients came from the Allegheny County Registry, 
were diagnosed at an older age (p<0.05) but had similar diabetes duration compared to those 
coming from the hospital registry. This pattern is consistent with a bias for younger cases at 
onset to be referred to the specialist Children’s Hospital. 
The inadequacy of death certificate classification alone has long been recognized, both 
generally and in Type 1 diabetes (West KM, 1979). The application of the standardized 
procedures has led to a major redistribution of the causes of death (DERI Study Group 1991). 
These changes resulted from both the review process and the inappropriate completion of the 
original death certificate (in many cases the last mentioned item was clearly not intended to 
be the underlying cause of death). Overall, in our analysis only 16 percent of the cases were 
decided by death certificate alone which contributed significantly to the accuracy of the 
results. Furthermore, the DERI mortality classification process itself provided a highly 
standardized, unique method to make more appropriate conclusions from cause-specific 
mortality data. Without the mortality classification committee review, the proportion of cases 
due to acute complications and kidney disease would have been seriously underestimated. 
The use of death certificates alone would have been too imprecise to determine differences in 
cause-specific mortality data across populations. 
Data from international studies also indicate that the proportion of deaths due to acute 
complications may have been seriously underestimated, and that acute complications may 
account for 33 percent of deaths among individuals with Type 1 diabetes within the first 20 
years (DERI Study Group Diabetes Care 1991) and were either the first or the second leading 
cause of death in patients from Finland, Japan and Israel (DERI Study Group Diabetes Care 
1991) in the early years. Other studies investigating mortality of Type 1 diabetes in children 
with 20 years of onset showed that one-third to one-half died of acute complications, mostly 
due to diabetic ketoacidosis (Laing SP 1999, Scibilia J 1986, Hirasing RA 1995). A 
substantial number of deaths may occur at the onset of the disease (Thordarson H 1995), 
suggesting that delayed diagnosis may contribute to excess mortality.  
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In our current analysis, however, only five children died from acute complications within one 
year of diagnosis so this alone cannot explain the difference. Overall, in the current report, we 
found that 45 percent of African Americans and 15 percent of Caucasian deaths resulted from 
acute complications. 
Regarding deaths from chronic diabetes complications, our findings are consistent with the 
literature showing cardiovascular diseases and nephropathy are responsible for most 
premature mortality in people with 26-year long Type 1 diabetes. A pervious analysis of the 
Allegheny County cohort reported that 2% of people with childhood-onset T1D died every 
year between the age of 25 and 40 years which is 20 times greater than the mortality of the 
USA general population (JS Dorman 1984). This excess is predominantly caused by acute 
complications (in the first decade of diabetes) and CAD (in the second and third decades). 
Infectious diseases are also contributed to the premature deaths probably reflecting poor 
glycemic status in these subjects, however, data about long-term glycemic control and 
treatment regimes were not available in our study.  
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6.2. Differences in mortality between Havana and Allegheny County 
 
This comparative study showed a dramatically higher mortality among people with childhood 
onset T1D in Havana, Cuba than in Allegheny County, USA. Type 1 diabetes is an 
uncommon disease in Cuba where incidence rates among children were 4-7 times lower than 
in the US (Karvonen M 2000), this may partly explain the much higher mortality in Havana. 
We found further significant differences in the cause specific mortality patterns. More deaths 
in Allegheny County were attributed to acute complications than to any other cause, while in 
the Havana cohort the leading cause of death was nephropathy, which accounted for nearly 
half of the deaths. Interestingly the mortality rate for acute complications was lower in 
Havana than in Allegheny County (although this difference was not significant) while renal 
mortality was eight times higher in Havana than in the Allegheny County cohort. The lower 
acute complication mortality rate found in Havana might be due to the existence of universal 
care in Cuba that makes minimal care available to most of the patients. Ready access to acute 
care may reduce acute complications such as diabetic ketoacidosis which has been found as a 
major reason in deaths from acute complications in the USA. On the other hand the higher 
renal disease mortality may reflect the limited resources which prohibit adequate long-term 
care as that for advanced renal disease. In present-day Cuba, dialysis services are universally 
provided free of charge. However, there is no information regarding the availability of those 
services for patients with chronic renal disease in the past, during the study period. 
Unavailability of dialyses services were also likely to relate the high renal mortality in T1D in 
Japan seen in the early DERI reports (Nishimura R 1996). The DERI study reported that much 
of the premature mortality related to T1D was potentially preventable (DERI Study Group 
Diabetes Care 1991). It showed that the higher mortality rates in the Japanese cohort were 
basically due to a high proportion of deaths related to acute complications (42%) and kidney 
diseases (33%). Israel and Finland had lower mortality rates for both nephropathy and acute 
complications. The mortality related to nephropathy reported here was higher in the Cuban 
(405.1 per 100,000 person-year) cohort than in the DERI Japanese cohort (276.7 per 100,000 
person-year). The low mortality rate attributed to cardiovascular diseases reported here may 
be due to the fact that the studied individuals are still relatively young. 
A study using information from long-term follow-up of patients from the Joslin Clinic, 
showed that a combination of advances in diabetes therapy and in the control of infection 
brought substantial improvement in survival of people with diabetes (Marks HH 1964). Other 
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aspects related to long-term diabetes care such as the use of HbA1c (Goldstein DE 1980), 
blood glucose self-monitoring (Consensus statement 1987) and the use of preventive drugs 
such as angiotensin-converting-enzime inhibitors and angiotensin II receptor blockers in the 
prevention of diabetic nephropathy (Lewis EJ 1993) may have also played a role in the 
different mortality pattern showed here although they only became available toward the end 
of the observational period. While mortality in Allegheny County was clearly related to acute 
care (47% combining acute complications and infections), the Cuban mortality was related 
mainly to long term care (48% nephropathy). Similar results from Allegheny County have 
been described previously (Tull ES 1996). Mortality in the Havana city cohort was mainly 
related to long-term care and therefore linked to lack of resources such as availability of 
dialysis services or long-term glycemic control.  
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6.3. The effect of year of diagnosis and temporal trends in mortality 
 
In an earlier report of the DERI study mortality, especially after 15 years duration of diabetes 
has declined during the last 30 years (Nishimura R 2001). The decline was most evident for 
the cases diagnosed in 1975–1979 compared with 1965–1969. SMRs at 20-year duration of 
diabetes showed a decreasing tendency over the study period, indicating that the improving 
prognosis of diabetic children was greater than that of the general population. The decline in 
mortality seemed to be similar in both Caucasians and African-Americans, although the 
prognosis of African-Americans with Type 1 diabetes was much worse than that of 
Caucasians after 25 years of diabetes. This has been revealed also by the combined 
DERI+EDC analysis. The timing of these improvements is consistent with the introduction of 
HbA1c testing, home blood glucose monitoring, and improved blood pressure therapy in the 
1980s. The decline in mortality seen in the cohort diagnosed in 1975–1979 may reflect an 
improvement in prevention of long-term diabetic complications such as end-stage renal 
disease. 
Our results showed furthermore an encouraging significant decline in the chronic 
complication mortality among Caucasians, which may reflect improvements both in the 
treatment and prevention of life-threatening, long-term diabetes complications such as end-
stage renal disease and coronary heart disease. In our study, the decline in mortality for both 
complications was approaching significance (p=0.06). Similar borderline significant decline 
was seen in the mortality from chronic complications among African Americans. However, 
while acute complication mortality did not change much over time among Caucasians, there 
was a big improvement in Africans-Americans for those diagnosed in 1975-1979 compared to 
those diagnosed in 1965-1969. 
In the Allegheny County-Havana comparative study improvements in survival have also been 
shown, however, it was not possible to expand the analysis to 1999 due to the lack of follow-
up information in the Havana city cohort. 
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6.4. Racial and gender differences in mortality 
 
Racial differences 
The results of our analyses confirm those of prior reports using the Allegheny County 
Registry (Nishimura R 2001, Dorman JS 1984). In particular they support and extend the 
prior demonstrations of an excess total mortality in African-Americans after 20 years of 
duration (Nishimura R 2001) and 25 years maximum follow-up (Tull ES 1996). The current 
study has a maximum of 36-year follow-up and in addition to showing a four-fold difference 
between the African-Americans and Caucasians overall, also demonstrates the excess rate is 
largely related to acute complications.  
One possible bias should be, however, mentioned regarding the identification of causes of 
death in the combined DERI+EDC study. Namely, that there was a difference in the 
availability of medical documents between African-Americans and Caucasians. The causes 
were decided by death certificates alone for only 14 percent of Caucasians but for 30 percent 
of African-Americans. It is possible therefore, that the classification may be less accurate in 
African-Americans and that we may have “overestimated” the deaths from acute 
complications. The truth is, however, that even if these “death certificate only” cases were 
excluded an excess would still be apparent. 
Whether our findings are the results of a specific diabetes effect or of a more general racial 
disparity is difficult to determine, particularly as death from acute complications is likely to 
be the first manifestation of a general disadvantage. On the other hand, because the total 
mortality in the general population is also higher in African-Americans, the standard mortality 
ratios, as reported earlier for diabetes are relatively similar in both races (Nishimura R 2001). 
Thus, the poorer prognosis for African-Americans with Type 1 diabetes might reflect an 
underlying general, racial disparity in socio economic status, health care access and/or 
utilization and behavior. Unfortunately these data are not available for the majority of subjects 
in this study. The Allegheny County Registry has previously attempted to separate out any 
ethnic effect from social class in terms of the incident of Type 1 diabetes. However this was 
difficult for most African-Americans were in the lowest social class. Within this group of 
African-Americans the authors found little relationship between incidence of diabetes and 
socioeconomic status (LaPorte RE 1981). Socioeconomic status and availability of 
specialized care may not explain all of the present racial disparity in diabetes mortality rates 
and further exploration of possible culturally related factors would appear to be appropriate. 
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Although it has been proposed that some African-American individuals may have a different 
type of diabetes, namely phasic or “J” type, we think this is an unlikely explanation of our 
findings as this type of diabetes typically has an older onset than our subjects and is ketosis 
resistant (Morrison EY 1995). 
The breakdown of death by race in the Allegheny County-Havana comparative study suggests 
that mortality in Allegheny County for African-Americans was worse than for Caucasians but 
similar to that seen in Havana for Hispanics. In cause-specific data by race, acute 
complication and infection related mortality clustered among African-Americans and this was 
responsible for most deaths among individuals in the Allegheny County cohort. While 
Hispanics had much higher mortality rate from nephropathy also when compared to African-
Americans although in this case, confidence intervals are overlapped perhaps due to the low 
number of African-American cases. These racial differences can be explained mainly by the 
different health care systems of USA and Cuba (different access to acute and long-term care) 
and not likely by other specific race related factors (see section 6.2.).  
 
Gender differences 
The DERI study found that the male/female mortality ratio varied depending on where the 
person lived and the overall incidence; for example Finland and Allegheny County had higher 
mortality rates among men than among women while the opposite was evident for Japan and 
Israel (DERI Am J Epidemiol 1991). Though, we found lower mortality rates among males 
than females in the Allegheny County cohort and the opposite in the Havana City cohort, the 
differences were not significant. The World Health Organization Multinational Study of 
Vascular Disease in Diabetes reported an excess in male as compared to female mortality 
(2.50) in the Havana cohort of people with Type 1 diabetes (Wang SL 1996). In our study 
there was no gender differences found in SMR. 
It is interesting to note that in the combined DERI+EDC cohort, the excess African-American 
mortality risk due to acute complications appears in both sexes, though it seems a little more 
marked in females. The reason for this is not clear, but it is consistent with our previous 
general findings (Tull ES 1996) and may relate to differences between males and females in 
risk factors for premature mortality from Type 1 diabetes (Dorman JS 1984). In this study, we 
also found that males were more likely to die from non-diabetes related causes than females. 
This is consistent with the literature, which demonstrates a greater number of accidents and 
suicides among young men than women (DERI Study Group Diabetes Care 1991). It should 
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also be noted that the Mortality Classification Committee has fully reviewed each death to 
determine the role of diabetes.  
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6.5. Incidences and predictors of CAD and nephropathy (MA, ON, ESRD) 
 
Incidence of CAD and MA / ESRD 
According to the results of DERI complication survey, the incidence of CAD increases 
dramatically after 25 years of diabetes duration reaching a cumulative incidence rate of 28% 
at 30 years. A decreasing incidence of diabetes complications, particularly overt nephropathy 
has been reported in the Type 1 diabetes population around the world over the past 15–20 
years (Hovind P 2003, Nordwall M 2004). Mortality rates have also been decreasing (Dorman 
JS 1984, Nishimura 2001), most likely reflecting better management and the declining 
morbidity. Improved metabolic control, facilitated by the advent of self-monitoring of blood 
glucose and HbA1c testing and stimulated by the results of the Diabetes Control and 
Complications Trial (DCCT 1993), along with better blood pressure management (Hovind P 
2003, Nordwall M 2004, Dorman JS 1984, Nishimura 2001) are likely to be major 
contributors. 
Two recent prospective epidemiological studies, the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) study (Orchard TJ 2003) and EURODIAB (Soedamah-Muthu SS 2004), 
a multicenter, clinic-based study in Europe, reported an incidence of total coronary events 
(including electrocardiogram [ECG] changes) of 16% over 10 years and 9% over 7 years, 
respectively, of follow-up in Type 1 diabetic patients. As the mean age at baseline was ∼30 
years, these incidence rates reflect the experience of those aged in their late 30s. In EDC, total 
CAD incidence (including angina and ischemic ECG changes) was >2% per year for those 
aged ≥35 years. A more recent report (Pambianco G 2006), using 12-year follow-up data, 
suggested annual major CAD event (myocardial infarction [MI], fatal CAD, or 
revascularization) rates of 0.98% for those with diabetes durations of 20–30 years (aged, on 
average, 28–38 years). These event rates were the same for both sexes, indicating a loss of the 
protection from CAD mortality that can be seen in females without diabetes experience. This 
is consistent with our findings in the DERI complication survey that the incidence rates are 
independent of gender and race.  
We could not show any decline in the cumulative incidences of CAD in the DERI survey 
study which is supported by the EDC study (Pambianco G 2006) reporting no difference in 
the cumulative incidence of CAD by 20, 25, or 30 years’ duration according to the year of 
diagnosis (1950 –1980). The benefits of improved diabetes care, therefore, do not (at least as 
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yet) appear to have reduced CAD morbidity, although a nice decline in CAD mortality by the 
year of diagnosis could be seen.  
 
Our findings regarding the 5-year incidence/prevalence rate of early microalbuminuria is 
mostly consistent with previous data in the literature. Cross-sectional studies show 8-13% 
rates among children with a mean age of 14 years and 5-year duration of diabetes (Salardi S 
1990, Norgaard K 1989, Cook JJ 1990). In one small longitudinal study with relatively low 
number of patients involved, Rudberg at al. found MA in 11% of the studied patients 7 years 
after the diabetes diagnosis (Rudberg S 1993).  
Estimates of the prevalence of MA during childhood are confounded by the effects of puberty, 
as indicated by the documentation in several studies that MA is rare before puberty, even in 
individuals with diabetes of long duration (Norgaard K 1989, Rudberg S 1993). Furthermore, 
most studies of MA in children have been cross-sectional, with only a few being longitudinal 
(Almdal T 1994, Rudberg S 1993). When longitudinal studies have been undertaken, they 
have been clinic- rather than population-based, and the sample sizes have been relatively 
small (Barkai L 1998, Jones CA 1998). Determination of the prevalence of MA in relation to 
age, sex, duration of diabetes, glycemic control, and puberty and of the predictive value of 
MA in childhood was purposed in a large prospective population-based study (Schultz CJ 
1999). The authors found a prevalence rate of 13% in a given geographic region in children 
with a median diabetes duration of five years (Schultz CJ 1999). 
 
In our DERI complication survey data, the cumulative incidence rate of ESRD was 11.3 % at 
25 years after onset. Klein et al. reported that cumulative incidence of renal insufficiency 
(serum creatinine >=2.0 mg/dl) and ESRD in a population-based cohort from Wisconsin was 
14.4% at 10 years (Klein R 1999). In the EDC study based on children diagnosed with T1D at 
Children's Hospital of Pittsburgh between 1950 and 80, the cumulative incidence of renal 
failure at 25 years has declined from 21% to 9% for those diagnosed in the 1950’s to the 70’s, 
respectively. (Orchard TJ 2002). Differences in methodology, renal endpoints, definitions of 
ESRD and population characteristics make it difficult to compare these results. As few 
population based reports are available regarding the incidence of ESRD in T1D, international 
comparisons using cohorts diagnosed by the same criteria are thus of particular interest. Our 
previous report from the DERI study, which focused on the incidence of dialysis in Japan and 
Allegheny County, USA suggested that the rate in Allegheny County was lower than that in 
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Japan (Matsushima M 1995). Our observation period in the current study is now twice of that 
of the previous report, so further international comparison would be needed. 
The EDC data suggests that natural history of Type 1 diabetes complications is generally 
improving, with major declines in total mortality and renal failure rates in individuals 
diagnosed after the mid-1960s. However, declines are not so impressive for overt nephropathy 
and any favorable patterns seen at 20 years have largely disappeared by 25 years’ duration 
(Pambianco G 2006). In terms of temporal trends of ESRD, the current study indicates that a 
significant improvement has occurred especially between the cases diagnosed between 1965-
69 and 1970-74. These results are consistent with a study in southeast Sweden indicating that 
cumulative incidence of persistent albuminuria declined among cases diagnosed between 
1965 and 1980 (Arnqvist HJ 1994). An earlier decline in the incidence of diabetic renal 
disease reported for the cases diagnosed between 1930-50 (Krolewski AS 1985, Andersen AR 
1983) was suggested to be due to improved metabolic control following the introduction of 
urine tests in 1950’s, highly purified insulin in 1950’s and blood glucose monitoring in 1970’s. 
(Kofoed-Enevoldsen A 1987). The reasons for the current decline in the ESRD is likely to 
reflect the introduction of better anti-hypertensive therapy (Goldstein DE 1980), especially 
ACE inhibitors introduced in clinical practice in 1980’s (Lewis EJ 1993), and better glycemic 
control following the introduction of HbA1c testing (Lewis JB 1999) and home blood sugar 
monitoring (Consensus 1987) in 1980's.  
The dramatic decrease over time in the cumulative incidence of mortality and renal failure is 
consistent with two reports from the Allegheny County registry (Nishimura R 2001) and an 
Israeli mortality study (Modan M 1991). Despite the declining rate, however, a major excess 
mortality still exists in the Type 1 diabetes population compared with non-diabetic 
populations (National Diabetes Data Group 1995). 
Our results from Allegheny County demonstrated a higher incidence of ESRD among 
African-Americans but an encouraging decline also in incidence for these diagnosed more 
recently. Similar findings have been reported in Type 2 diabetes (Cowie CC 1989). As a 
higher total mortality among African Americans with T1D have been reported in Allegheny 
County (Nishimura R 2001, Tull ES 1996), the role of ESRD in this disparity has not yet 
revealed. 
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Predictors of CAD and ON / MA 
In our follow-up analysis based on the EDC study, traditional risk factors such as age and 
triglycerides were revealed as independent predictors of CAD while glycemic status and 
insulin resistance proved to be related to the development of nephropathy. Thus, our data 
supports previous suggestions that insulin resistance may play a role in the development of 
Type 1 diabetes complications, particularly overt nephropathy (Erbey JR 1999, Stuhldreher 
WL 1992). Fibrinolytic factors such as PAI-1 and its complexes with tPA did not show any 
direct effect on the development of CAD, however, strongly related to eGDR (marker of 
insulin resistance), independently of age, and thus are likely to be involved in the 
pathogenetic pathway. 
An association between hypofibrinolysis and diabetes has previously been recognized (Almer 
LO 1983, Fuller JH 1979). It has been also shown from earlier studies that several well 
established cardiovascular risk factors such as smoking (Meade TW 1979, Simpson AJ 1998), 
hypertriglyceridemia (Hamsten A 1985, Simpson AJ 1998) and obesity (Almer LO 1975) are 
also associated with a decrease in fibrinolytic activity. In particular the association with 
triglycerides are relevant to the current analyses, as both fibrinolytic variables were 
significantly correlated with triglycerides which was the major independent multivariate 
predictor of CAD. It is thus likely that if triglycerides contribute above and beyond their 
association with fibrinolysis (as seems likely) that they would be a stronger statistical 
predictor, even though some of that prediction may represent altered fibrinolysis. 
Since deep assessment and analysis of potential traditional and novel predictors for CAD and 
ON was not the main purpose of our current study, it has limitations addressing this very 
complex issue, although results are consistent with other EDC analysis employed an extensive 
array of risk factors and involved stored plasma/serum samples acquired over the 10-year 
follow-up. In this study the results suggest that glycaemic exposure, insulin resistance, and 
possibly oxidative damage may be important ‘initiators’, while blood pressure and lipids have 
a greater role as accelerators later in the process (Yishak AA 2006). These results are 
consistence with our findings in a different substudy of the same cohort which was focusing 
on the fibrinolytic changes in T1D. Our earlier observations (Orchard TJ Kid Intl 2002) 
showed similar effects using a different temporal analysis, i.e. eGDR and HbA1 predict overt 
nephropathy over the long term (5–10 years post-measurement), while blood pressure and 
lipids predict in the short term (0–5 years post-measurement). Furthermore, though fibrinogen, 
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pulse and eGDR were significant univariate predictors of overt nephropathy, these did not 
appear to contribute independently of log AER, log IgG and LDL particle size.  
Urinary albuminuria (AER) was proved to be a strong independent predictor of overt 
nephropathy in agreement with earlier reports (Mogensen CE 1984). A deleterious influence 
of serum total or LDL cholesterol on renal function decline and/or progression of albuminuria 
has been previously reported among individuals with Type 1 diabetes. It seems likely that it is 
mainly the small dense LDL particles that are related to incidence of overt nephropathy, as it 
has also been reported for CAD in this cohort (Soedamah-Muthu SS 2003). Interestingly, this 
latter analysis showed HDL subclasses 4 and 5 to be independently (negatively) related to 
CAD, while a positive correlation was observed for H3 subclass. No such associations were 
seen in this analysis for overt nephropathy. In a similar nested case–control study from the 
EURODIAB cohort by Chaturvedi (Chaturvedi N 2002), elevated cholesterol, triglycerides, 
LDL, Apo B and diminished LDL particle size were associated with albuminuria, although 
LDL subclasses were not measured. 
Some similarities can be observed with CAD predictors (e.g. LDL particle size), whereas 
other factors predictive of CAD in this cohort (e.g. VLDL subclasses, hypertension) do not 
seem to be as strongly related to overt nephropathy. Nonetheless, the results are consistent 
with the hypothesis that similar risk factors may accelerate disease in both the arterial blood 
vessels (atherosclerosis) and glomerulus (glomerulosclerosis), when they are damaged by 
initial oxidation (particularly the former) and/or glycosylation (particularly the latter). 
 
Several factors can influence the development of early microalbuminuria in children with 
Type 1 diabetes. According to Schultz at al. the cumulative probability of developing MA 
during childhood is related to sex, HbA1c, duration of diabetes, and pubertal status. MA is 
rare before puberty except in those who were 5 years of age at diagnosis of diabetes. 
Although these factors affect MA prevalence in childhood, the cumulative probability is 
similar irrespective of age at diagnosis, indicating the importance of glycemic control and 
diabetes duration in the pre-pubertal years (Schultz CJ 1999). 
In contrary, in our study examining 5 and 10-year follow-up results of patients with childhood 
(<18 years) onset Type 1 diabetes, we found no effect of glycemic control and other 
traditional risk factors on the development of early microalbuminuria. This discrepancy might 
be probably explained by the generally high baseline HbA1c values and the relatively low 
number of subjects involved. Our main result, however, supports earlier findings that 5-year 
incidence of MA is significantly lower among patients with early childhood (0-4 years) onset 
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T1D compared to those in higher age groups (5-9, 10-17 yrs) by diabetes onset. Biologic 
maturity measured by the Tanner-score determines strongly the progression to MA 
confirming the results from large studies that hormonal changes in puberty can accelerate the 
development of microalbuminuria in children with diabetes.  
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6.6. Survival after CAD–revascularization and ESRD–renal replacement therapy 
 
According to our results the incidence of non-fatal myocardial infarction and 
revascularization therapy increased dramatically after two and a half decades of diabetes 
duration, however, probably due to the benefits of RV and other conservative-preventive 
therapies in those who developed CAD, the incidence of fatal MI remained relatively stable.  
The BARI (Bypass Angioplasty Revascularization Investigation) randomized trial was 
designed to test whether percutaneous transluminal coronary balloon angioplasty (PTCA) 
compromised 5-year survival compared with coronary artery bypass grafting (CABG) in 
patients with multivessel coronary artery disease. After 5 years of follow-up, overall survival 
was similar for the two revascularization strategies (BARI Investigators 1996); however, after 
7 years of follow-up, CABG survival was statistically superior (BARI Investigators 2000). An 
unexpected finding of the BARI trial was that among patients without treated diabetes, 
survival rates for the PTCA and CABG randomized groups were almost identical throughout 
the 7 years of follow-up, whereas among patients with treated diabetes, the CABG group had 
significantly better survival. The survival difference was attributable to reduced cardiac 
mortality (BARI Investigators 1997). This result was confirmed also by the final – 10-year 
follow-up – data of the BARI cohort. 
In patients with Type 2 diabetes, CABG conferred a consistent, clinically relevant, absolute 
survival benefit over balloon angioplasty that diminished somewhat over extended follow-up 
because patients in both groups had higher event rates. Five-year mortality results from 
Arterial Revascularization Therapies Study (ARTS) - diabetes: 13.4% stents vs. 8.3% CABG, 
relative risk =1.61, p=0.27; no diabetes: 6.8% stents vs. 7.5% CABG, relative risk=0.91, 
p=0.71 - (Abizaid A 2001) support the finding that CABG may have particular advantages for 
patients with diabetes. It remains to be seen whether advances in percutaneous procedures and 
medical management over the past decade will make contemporary angioplasty a reasonable 
option in this cohort. The steady incidence of cardiac events over the 10 years of follow-up in 
both treatment groups in the BARI study emphasizes that coronary revascularization does not 
reverse the underlying pathophysiology of coronary disease.  
In our results from the DERI survey both forms of revascularization therapy seemed to be 
beneficial even in patients without myocardial infarction thus providing support for the early 
revascularization of Type 1 diabetes individuals with CAD. There was no significant 
difference found between the revascularization strategies probably due to the considerably 
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low number of CAD deaths and events. Further limitation of the study is that it was based on 
self-reported data (Appendix 1.) where exact definition of myocardial infarction could not be 
made and no other relevant factors (glycemic control, smoking, lipid levels and other risk 
factors) were collected. 
The introduction of coronary stents and other technical refinements in angioplasty and surgery 
did not alter the conclusion from these results. Although some might argue that these 
procedural refinements make the results obsolete, we believe that our observations with 
respect to death and MI remain applicable to contemporary practice. Overviews of the 
randomized trials of bare metal stents (Brophy JM 2003, Kandzari DE 2006) and drug-eluting 
stents (Babapulle MN 2004, Tsimikas S 2006) show that these devices have no significant 
advantage regarding mortality or MI compared with balloon angioplasty despite striking 
reductions in rates of restenosis and repeat revascularization procedures. Furthermore, 
observational studies of patients undergoing angioplasty indicate that restenosis does not 
confer a worse prognosis concerning survival (Weintraub WS 1993). Underuse of evidence-
based medical therapies is unfortunately common among patients with coronary disease. 
Clinical outcomes for all patients may be improved further by providing long-term aggressive 
medical management after revascularization. 
 
As a result of our analysis in the Allegheny County cohort (DERI study), the cumulative 
survival after end-stage renal disease (ESRD) improved by the year of diabetes diagnosis 
probably reflecting better access and care in patients with renal disease. 
Approximately half of the subjects survived 10 years after the introduction of renal 
replacement therapy (RRT) in the current study. The declining tendency in mortality of ESRD 
did not reach statistical significance, probably because of the small number of events. It thus 
is critical that a longer observation period be examined in the future. 
Cowie et al reported that mean survival of African-Americans after RRT was shorter than 
Caucasian (Cowie CC 1994), however, in this study, little difference was observed, and in 
multivariate analyses race did not affect the prognosis. Though, the incidence rate of ESRD in 
African-Americans was significantly higher than that of Caucasians, once they had ESRD, the 
risk of death was not greatly affected by race. 
In the 1970’s and 1980’s, many reports indicated that renal transplantation offered better 
survival than dialysis (Khauli RB 1986, Parfrey PS 1985). According to United States Renal 
Data System (USRDS) coordination center (USRDS 2001), expected survival of transplant 
recipients was more than twice that of dialysis recipients in the same age range, and the 5-year 
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survival after dialysis alone, transplantation from cadaveric donor and transplantation from 
living donor were 29.2%, 75.2% and 83.0%, respectively in diabetes patients (USRDS 2001). 
In the current study, the transplant recipients also had a better survival than patients on 
dialysis, and the 5-year survival after dialysis alone (32.8%) and transplantation (79.6%) 
observed in this study were similar to USRDS. Part of the better survival is likely to be 
explained by the fact that healthier patients are placed on the waiting list for transplantation, 
so that long-term survival is better among those on the waiting list who eventually undergo 
transplantation (Wolfe RA 1999). In a report by Wolfe et al., the relative risk of death 
following cadaveric transplantation compared to dialysis awaiting transplantation was as low 
as 0.18 in the 20-39-year age group with diabetes (Wolfe RA 1999). The absolute risk was not 
comparable with this study, as the methodology was different, however, the relative risk 
(0.25) was similar. 
Individuals treated with pancreatic-kidney transplantation have also been reported to have a 
better survival than those undergoing kidney transplantation alone (Becker BN 2000, Smets 
YF 1999). In our current study, pancreatic-kidney transplantation recipients tended to have 
better survival than kidney transplant recipients. The difference, though large, did not reach 
statistical significance in life table analysis and Cox time-dependent analyses as the number 
of the events were relatively small, reflecting the more recent introduction of pancreatic-
kidney transplantation. Longer follow-up will be necessary to evaluate this issue in this cohort.  
One of the limitations of our study is that we could not ascertain end-stage renal complication 
status for 15 percent of the cases whose living status was confirmed, due mainly to participant 
reluctance or that of their relatives, including parents, to allow us to contact subjects. 
Although survival after RRT was higher with transplantation compared to dialysis alone, 
these data do not permit a full evaluation as we had no details concerning the clinical state of 
subjects at the onset of RRT. It is likely that those with more severe co-morbidities were not 
transplants candidates.  
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7. Summary and conclusion 
 
The introduction of insulin into clinical use in the 1920s dramatically changed the life of 
children with Type 1 diabetes. Although much of progression has so far been achieved in their 
life-expectancy and life quality, health outcome indicators are still proved to be worse in Type 
1 diabetes patients compared to non-diabetic population. Individuals who develop diabetes 
remain at substantially greater risk of early mortality in which the major microvascular and 
macrovascular complications of diabetes play an essential role. 
The presented studies are expected to give epidemiological answers to the number of issues 
concerning childhood-onset Type 1 diabetes mortality, its major complications and the link 
between them. My theses below are based upon these major findings. 
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7.1. Theses 
 
a) Beyond the unexpectedly common acute complications, coronary artery disease as a 
macrovascular and renal disease as a microvascular chronic complication attributed 
significantly to premature deaths of patients with Type 1 diabetes. 
 
b) Racial differences in cause-specific mortality from Type 1 diabetes have been revealed. 
The excess mortality among African-American diabetes patients is particularly linked 
to acute diabetes complications, mainly diabetic ketoacidosis, perhaps reflecting poor 
health care access or utilization. In Hispanics, however, the leading cause of death 
seems to be nephropathy which may reflect limited resources for those with advanced 
renal disease. While mortality in the US was clearly related to acute care, excess 
mortality in Cuban patients was mainly attributable to long-term care reflecting the 
effects of two largely different health care systems on mortality and outcomes. This 
can lead us to the conclusion that different strategies might be needed to improve 
survival among individuals with Type 1 diabetes in USA and Cuba. 
 
c) An encouraging improvement has been achieved overall in the 20-year mortality rates 
for all major causes (especially chronic diabetes complications among Caucasians) by 
calendar year of diagnosis probably due to the better preventive strategies of the recent 
years, though African-Americans are still more likely to be affected by diabetes-
related deaths. Since acute complications of diabetes may be the most amenable to 
intervention, a focus on their prevention should be a high priority.  
 
d) Incidence of overt nephropathy has been nicely decreasing in recent years, however, 
the benefits of improved diabetes care, at least as yet, do not appear to have reduced 
morbidity of coronary artery disease, although a nice decline in their mortality by the 
year of diagnosis can be seen. This might also be explained by different predictors 
affecting the development of renal disease and coronary artery disease, as glycemia 
itself can more directly contribute to the former one while insulin resistance rather 
play a big role in the latter complication. 
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e) The development of early microalbuminuria might be considerable in children within 
five years of diabetes duration. Age at onset and pubertal maturity largely contribute 
to the risk of microalbuminuria. Although HbA1c might be less related to the early 
development of microalbuminuria, poor glycemic status may have long-term 
consequences for the risk of subsequent nephropathy and for cardiovascular risk in 
postpubertal children. 
 
f) Once complication developed, right tertiary prevention strategy should be planned to 
improve life quality and prolong life-years. Both forms of revascularization therapy 
(i.e. coronary artery bypass grafting and percutaneous transluminary coronary 
angioplasty) might be beneficial for patients with Type 1 diabetes who underwent 
myocardial infarction. Our data also provide support for early revascularization as a 
secondary prevention strategy showing better survival in those who undergo 
revascularization before the irreversible myocardial event. The incidence of end-stage 
renal disease requiring some form of renal replacement therapy shows an encouraging 
decline for those patients diagnosed more recently. Survival after renal replacement 
therapy is greater with transplantation compared with dialysis therapy alone. 
Combined pancreatic-kidney transplantation seems to be beneficial over renal 
transplantation alone. 
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7.2. Conclusive remarks 
 
These epidemiological data might help diabetes specialists in order to use appropriate 
prevention strategies in their everyday clinical practice and diabetes care, nevertheless they 
might contribute to a better understanding in the natural history of the disease.  
The challenge to society is to deliver intensive diabetes therapy to Type 1 diabetic patients at 
large, in a cost-effective manner, by teams with appropriate expertise. Our data suggest 
optimism toward the way that adequate diabetes care will become available to all children and 
adolescents who developed the disease, thus they achieve life expectancy and life-quality 
same as in the general population. 
  98
8. References 
 
 
Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus 
on percutaneous and surgical treatment of multivessel coronary disease patients: insights from 
the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533–8. 
 
Almdal T, Norgaard K, Feldt Rasmussen B et al.: The predictive value of micro albuminuria 
in IDDM: a five-year follow-up study. Diabetes Care 17:120–125, 1994 
 
Almer LO, Janzon L: Low vascular fibrinolytic activity in obesity. Thromb Res 6: 171-175, 
1975. 
 
Almer LO, Sundkvist G, Lilja B: Fibrinolytic activity, autonomic neuropathy, and circulation 
in diabetes mellitus. Diabetes 32 (S2): 4-7, 1983. 
 
Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. : Diabetic nephropathy in 
Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 25:496-501, 
1983 
 
Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. : Declining incidence of 
nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 330:15-8, 1994. 
 
Babapulle MN, Joseph L, Belisle P et al., A hierarchical Bayesian meta-analysis of 
randomised clinical trials of drug-eluting stents. Lancet 364: 583–591, 2004. 
 
Barkai L, Vamosi I, Lukacs K: Enhanced progression of urinary albumin excretion in IDDM 
during pubert y. Diabetes Care 21:1019–1023, 1998 
 
Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective 
on an old paradigm. Diabetes 48:1–9, 1999. 
 
Beck AT, Garbin MG: Psychometric properties of the Beck Depression Inventory: 25 years of 
evaluation. Clin Psychol Rev 8:77-100, 1988. 
 
Becker BN, Brazy PC, Becker YT, et al. Simultaneous pancreas-kidney transplantation 
reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int 
2000; 57: 2129-2135. 
 
Bevilacqua MP: Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11:767– 804, 
1993. 
 
Borch-Johnsen K & Kreiner S. Proteinuria: Value as predictor of cardiovascular mortality in 
insulin dependent diabetes mellitus. BMJ 294: 1651−1654, 1987. 
 
Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in 
Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28: 590-596, 1985. 
 
  99
Borch-Johnsen K: The prognosis of insulin-dependent diabetes mellitus. Danish Med Bull 36: 
336-348, 1989. 
 
Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J: The 
hypertension detection and follow-up program. Prev Med 1976; 5: 207-215. 
 
Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical Bayesian 
meta-analysis. Ann Intern Med 2003;138: 777–86. 
 
CASS Investigators, Coronary Artery Surgery Study (CASS): a randomized trial of coronary 
artery bypass surgery. Survival data, Circulation 68: 939–950, 1983. 
 
Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease 
among persons with diabetes—United States, 1990-2002. MMWR Morb Mortal Wkly Rep 
2005;54:1097-1100. 
 
Chaturvedi N, Fuller JH, Taskinen M-R. Differing associations of lipid and lipoprotein 
disturbances with the macrovascular and microvascular complications of type 1 diabetes. 
Diabetes Care 2001; 24: 2071– 2077 
 
Christlieb AR, Warram JH, Krolewski AS, Busick EJ, Ganda OP, Asmal AC, Soeldner JS, 
Bradley RF: Hypertension: the major risk factor in juvenile-onset insulin-dependent diabetics. 
Diabetes 30 (Suppl. 2):90 –96, 1981. 
 
Collado-Mesa F, O. Diaz-Diaz, R. Melian-Torres, R. Suarez-Perez, M. Vera-Gonzalez, D. 
Aldana-Padilla, Mortality of childhood-onset IDDM patients: a cohort study in Havana City 
Province, Cuba, Diabetes Care 20: 1237–1241, 1997. 
 
Colhoun HM, Rubens MB, Underwood SR, Fuller JH: The effect of type 1 diabetes mellitus 
on the gender difference in coronary artery calcification. J Am Coll Cardiol 36:2160–2167, 
2000 
 
Consensus statement of self-monitoring of blood glucose. Diabetes Care 10:95-99, 1987 
 
Cook, JJ, Daneman, D: Microalbuminuria in adolescents with insulin-dependent diabetes 
mellitus. Am J Dis Child 144:234-237, 1990 
 
Costacou T, Ellis D, Fried F, Orchard TJ. Sequence of Progression of Albuminuria and 
Decreased GFR in Persons With Type 1 Diabetes: A Cohort Study. Am Journal Kid Dis 50: 
721-733, 2007 
 
Costacou T, Lopes-Virella MF, Zgibor J, Virella G, Otvos J, Walsh M, Orchard TJ: Markers 
of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes: the 
Pittsburgh Epidemiology of Diabetes Complication Study. J Diabetes Complications 19:183–
193, 2005. 
 
Cowie CC, Port FK, Rust KF, Harris MI. Differences in survival between black and white 
patients with diabetic end-stage renal disease. Diabetes Care. 17:681-687, 1994. 
 
  100
Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence 
of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 
321:1074-1079, 1989 
 
Crall FV Jr, Roberts WC: The extramural and intramural coronary arteries in juvenile diabetes 
mellitus: analysis of nine necropsy patients aged 19 to 38 years with onset of diabetes before 
age 15 years. Am J Med 64:221–230, 1978 
 
Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, 
Hamman RF, Rewers M: Effect of type 1 diabetes on the gender difference in coronary artery 
calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 
Diabetes (CACTI) Study. Diabetes 52:2833–2839, 2003 
 
Davies AG, Price DA, Postlethwaite RJ, Addison GM, Burn JL, Fielding BA: Renal function 
in diabetes mellitus. Arch Dis Child 60:299–304, 1985 
 
De Cosmo S, Argiolas A & Miscio G et al. A PC-1 amino acid variant (K121Q) is associated 
with faster progression of renal disease in patients with type 1 diabetes and albuminuria. 
Diabetes 49: 521−524, 2000 
 
De Cosmo S, Bacci S & Piras GP et al. High prevalence of risk factors for cardiovascular 
disease in parents of IDDM patients with albuminuria. Diabetologia 40: 1191−1196, 1997 
 
Deckert T, Poulsen JE, Larsen M: Prognosis of diabetics with diabetes onset before age 31. I. 
Survival, cause of death and complications. Diabetologia 14: 363-370, 1978. 
 
Deckert T, Poulsen JE, Larsen M: Prognosis of diabetics with diabetes onset before the age of 
31. II. Factors influencing the prognosis. Diabetologia 14: 371–377, 1978. 
 
Detre KM, Murphy ML and Hultgren H: Effect of coronary bypass surgery on longevity in 
high and low risk patients report from the VA Cooperative Coronary Surgery Study, Lancet 
2: 1243–1245, 1977. 
 
Detre KM, M.S. Lombardero, M.M. Brooks, R. Hardison, R. Holubkov, G. Sopko, R. Frye 
and B. Chaitman, The effect of previous coronary artery bypass surgery on the prognosis of 
patients with diabetes who have acute myocardial infarction, N Engl J Med 342: 989–997, 
2000. 
 
Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of 
diabetes on the development and progression of long-term complications in insulin-dependent 
diabetes mellitus. N Engl J Med 329: 977-986, 1993. 
 
Diabetes Epidemiology Research International Mortality Study Group: Sex differences in the 
mortality associated with insulin-dependent diabetes mellitus in four countries. Am J 
Epidemiol 133: 577-584, 1991. 
 
Diabetes Epidemiology Research International Mortality Study Group: International 
evaluation of cause-specific mortality in IDDM. Diabetes Care 14: 55-60, 1991. 
 
  101
Diabetes Epidemiology Research International Mortality Study Group: Major cross-country 
differences in risk of dying for people with IDDM. Diabetes Care 14: 49–54, 1991. 
 
Diabetes Epidemiology Research International (DERI) Study Group: International analysis of 
insulin-dependent diabetes mellitus mortality: a preventable mortality perspective. Am J 
Public Health 142:612–618, 1995. 
 
Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK et al. The 
Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. 
Mortality results. Diabetes;33: 271–276, 1984. 
 
Entmacher PS, Root HF, Marks HH: Longevity of diabetic patients in recent years. Diabetes 
1964; 13: 373-377. 
 
Erbey JR, Williams KV, Dorman JS, Orchard TJ: Insulin resistance is a risk factor for the 
development of complications in type 1 diabetes? Diabetes 1999; 48 (Suppl.1): A1316. 
 
European Coronary Surgery Study Group, Long-term results of prospective randomised study 
of coronary artery bypass surgery in stable angina pectoris, Lancet 2: 1173–1180, 1982. 
 
Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ: Are predictors of coronary heart 
disease and lower extremity arterial disease in type 1 diabetes the same? A prospective study. 
Atherosclerosis 148:159–169, 2000. 
 
Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal 
disease: A meta-analysis. Kid Intl 2001; 59: 260–269 
 
Fuller JH, Elford J, Goldblatt P, Adelstein AM: Diabetes mortality: new light on an 
underestimated public health problem. Diabetologia 24:336-341, 1983. 
 
Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WRS, Stirling Y: 
Haemostatic variables associated with diabetes and its complications. Br Med J 2: 964-966, 
1979 
 
Giunti S, Bruno G, Veglio M, Gruden G, Webb DJ, Livingstone S, Chaturvedi N, Fuller JH, 
Perin PC: Electrocardiographic left ventricular hypertrophy in type 1 diabetes: prevalence and 
relation to coronary heart disease and the cardiovascular risk factors: the Eurodiab IDDM 
Complications Study. Diabetes Care 28: 2255–2257, 2005. 
 
Goldstein DE, Walker B, Rawlings SS, et al: Hemoglobin A1c levels in children and 
adolescents with diabetes mellitus. Diabetes Care 3:503-507, 1980 
 
Goodkin G: Mortality factors in diabetes. J Occup Med 1975; 17: 716-721. 
 
Haffner SM, Lehto S, Ronnemaa T, Pyorala K and Laakso M: Mortality from coronary heart 
disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior 
myocardial infarction, N Engl J Med 339: 229–234, 1998. 
 
  102
Hamsten A, Wiman B, De Faire U, Blomback M: Increased plasma levels of a rapid inhibitor 
of tissue plasminogen activator in young survivors of myocardial infarction. N Eng J Med 
1985; 313: 1557-1563. 
 
Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I 
or type II diabetes mellitus. Nephrol Dial Transplant. 4:859-863, 1989 
 
Herlitz J, K. Malmberg, B.W. Karlson, L. Ryden and A. Hjalmarson, Mortality and morbidity 
during a five-year follow-up of diabetics with myocardial infarction, Acta Med Scand 224: 
31–38, 1988. 
 
Hirasing RA, Bohm FJ, Reeser HM, et al. Onset mortality of type I diabetes in 0- to 19-year-
old children in the Netherlands, 1988-1990. Acta Paediatr; 84:1197-1198, 1995. 
 
Hlatky MA, C. Bacon, D. Boothroyd, E. Mahanna, J.G. Reves, M.F. Newman, I. Johnstone, C. 
Winston, M.M. Brooks and A.D. Rosen et al., Cognitive function 5 years after randomization 
to coronary angioplasty or coronary artery bypass graft surgery, Circulation 96 (Suppl), II-
11–II-14, 1997. 
 
Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving H-H: 
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 
26:1258 –1264, 2003 
 
Jandrain B, Herbaut C, Depoorter J-C & Voorde KV. Long-term (1 year) acceptability of 
perindopril in type II diabetic patients with hypertension. Am J Med 1992; 92 Suppl 4B: 
915−945. 
 
Jarvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, Lehtimaki T, 
Ronnemaa T, Viikari J, Raitakari OT: Endothelial dysfunction and increased arterial intima-
media thickness in children with type 1 diabetes. Circulation 109:1750–1755, 2004. 
 
Jenkins AJ, Best JD, Klein RL, Lyons TJ: Lipoproteins, glycoxidation and diabetic 
angiopathy. Diabetes Metab Res Rev 20: 349–368, 2004. 
 
Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T: Coronary heart disease in 
young type 1 (insulin-dependent) diabetic patients with and without nephropathy: incidence 
and risk factors. Diabetologia 30:144 –148, 1987. 
 
Johnson DD, Palumbo DJ, Chu C: Severe diabetic ketoacidosis in a community-based 
population. Mayo Clinic Proc 1980; 55: 83-88. 
 
Joner G, Patrick S: The mortality of children with Type 1 (insulin-dependent) diabetes 
mellitus in Norwey, 1973-1988. Diabetologia 1991; 34: 29-32. 
 
Jones CA, Leese GP, Kerr S, Bestwick K, Isherwood DI, Vora JP, Hughes DA, Smith C: 
Development and progression of micro albuminuria in a clinic sample of patients with insulin 
dependent diabetes mellitus. Arch Dis Child 78:518–523, 1998 
 
 
  103
Jones RH, K. Kesler, H.R. Phillips III, D.B. Mark, P.K. Smith, C.L. Nelson, M.F. Newman, 
J.G. Reves, R.W. Anderson and R.M. Califf, Long-term survival benefits of coronary artery 
bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery 
disease, J Thorac Cardiovasc Surg 111: 1013–1025, 1996. 
 
Joslin EP, Wilson JL: Lessons for future treatment from 472 fatalities in diabetic children. Br 
Med J 1950; 2:1293-1296. 
 
Jougla E, Papoz L, Balkau B, Maguin P, Hatton F, the EURODIAB Subarea C Study Group: 
Death certificate coding practices related to diabetes in European countries. Int J Epidemiol 
1992; 21:343-352. 
 
Kandzari DE, Tuttle RH, Zidar JP, Jollis JG. Comparison of long-term (seven year) outcomes 
among patients undergoing percutaneous coronary revascularization with versus without 
stenting. Am J Cardiol 2006;97:1467–72. 
 
Kaplan MH, Feinstein AR: A critique of methods in reported studies of long-term vascular 
complications in patients with diabetes mellitus. Diabetes 1973;22:160-174. 
 
Karger S: Trends in mortality from young onset diabetes in Finland, Israel, Japan and the 
United States during 1950-1984. In Prognosis of Diabetes in Children. Laron Z, Karp M, Eds. 
Basel, Switzerland, 1989, p. 185-190 
 
Karvonen M, Viik-Kajander MV, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. For 
the Diabetes Mondiale (DiaMond) Project Group. Diabetes Care; 23:1516-26, 2000. 
 
Khauli RB, Novick AC, Steinmuller DR, et al : Comparison of renal transplantation and 
dialysis in rehabilitation of diabetic end-stage renal disease patients. Urology. 1986 27:521-
525. 
 
Klein BEK, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson ML, Moss SE, 
Reinke JO: Cardiovascular disease, mortality, and retinal microvascular characteristics in type 
1 diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 
164:1917–1924, 2004. 
 
Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal 
insufficiency in people with type 1 diabetes. Diabetes Care. 22:743-751, 1999 
 
Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T : Declining incidence 
of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark. Diabetes. 
36:205-209, 1987 
 
Koivisto VA, Stevens LK & Mattock MB et al. Cardiovascular disease and its risk factors in 
IDDM in Europe. Diabetes Care 1996; 19: 689−697.  
 
Kolkka R and Hilberman M: Neurologic dysfunction following cardiac operation with low-
flow, low-pressure cardiopulmonary bypass, J Thorac Cardiovasc Surg 79: 432–437, 1980. 
 
  104
Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, 
Christlieb AR, Bradley RF, Kahn CR: Magnitude and determinants of coronary artery disease 
in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750 –755, 1987. 
 
Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history 
of nephropathy in type I diabetes. Am J Med. 78:785-794, 1985. 
 
Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of 
type I diabetes mellitus and its complications. N Engl J Med. 317:1390-1398, 1987 
 
Krolewski M, Eggers PW, Warram JH.: Magnitude of end-stage renal disease in IDDM: a 35 
year follow-up study. Kidney Int. 50:2041-2046, 1996 
Laakso M and Lehto S: Epidemiology of macrovascular disease in diabetes, Diabetes Res 5: 
294–315, 1997. 
 
Laing SP, Swerdlow AJ, Slater SD, et al. British Diabetic Association Cohort Study, II: 
cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med; 
16:466-471, 1999. 
 
LaPorte RE, Orchard TJ,Kuller LH, et al.  The Pittsburgh insulin dependent diabetes mellitus 
registry: The relationship of insulin dependent diabetes mellitus incidence to social class. Am 
J Epidemiol; 114(3):379-384, 1981. 
 
Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K: Silent coronary 
atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. 
Diabetes 51: 2637–2641, 2002 
 
Lehto S, Ronnemaa T, Pyorala K, Laakso M: Poor glycemic control predicts coronary heart 
disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb 
Vasc Biol 19:1014–1019, 1999. 
 
Lester FT: Clinical features, complications and mortality in type 1 (insulin-dependent) 
diabetic patients in Addis Ababa, Ethiopia, 1976-1990. Q T Med 83:389-399, 1992. 
 
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group: The effect of 
angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–
1462, 1993 
 
Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ : Effect of intensive blood pressure control 
on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am JKidney Dis. 
34:809-817, 1999 
 
Lloyd CE, Kuller LH, Becker DJ, Ellis D, Wing RR, Orchard TJ: Coronary artery disease in 
IDDM: gender differences in risk factors, but not risk. Arterioscler Thromb Vasc Biol 16:720 
–726, 1996. 
 
Lopes-Virella MF, Virella G: Immune mechanisms of atherosclerosis in diabetes mellitus. 
Diabetes 41 (Suppl. 2):86–91, 1992. 
 
  105
Mark DB, L.C. Lam, K.L. Lee, R.H. Jones, D.B. Pryor, R.S. Stack, R.B. Williams, N.E. Clap-
Channing, R.M. Califf and M.A. Hlatky, Effects of coronary angioplasty, coronary bypass 
surgery, and medical therapy on employment in patients with coronary artery disease a 
prospective comparison study, Ann Intern Med 120: 111–117, 1994. 
 
Marks HH: Longevity and mortality of diabetics Am J Public Health 55:416–423, 1965 
 
Matsushima M, LaPorte RE, Maruyama M, Shimizu K, Nishimura R, Tajima N for the DERI 
Mortality Study Group: Geographic variation in mortality among individuals with youth-onset 
diabetes mellitus across the world. Diabetologia, 40: 212-216, 1997. 
 
Matsushima M, Tajima N, La Porte RE, et al. Markedly increased renal disease mortality and 
incidence of renal replacement therapy among IDDM patients in Japan in contrast to 
Allegheny County, Pennsylvania, USA. Diabetes Epidemiology Research International 
(DERI) US-Japan Mortality Study Group. Diabetologia: 38: 236-243, 1995. 
 
McCrary RF, Pitts TO, Puschett JB. Diabetic nephropathy: Natural course, survivorship and 
therapy. Am J Nephrol 1981;1:206-218. 
 
McLarty DG, Kinabo L, Swai AB: Diabetes in tropical Africa: a prospective study, 1981-7. II. 
Course and prognosis. BMJ 300:1107-1110, 1990. 
 
McNally PG, Raymond NT, Burden ML, Burton PR, Botha JL, Swift PG, Burden AC, 
Hearnshaw JR: Trends in mortality of childhood onset insulin-dependent diabetes mellitus in 
Leicestershire: 1940–1991. Diabet Med 12:961–966, 1995. 
 
Meade TW, Chakraberti R, Haines AP, North WRS, Stirling Y: Characteristics affecting 
fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-156. 
 
Miettinen H, S. Lehto, V. Salomaa, M. Mahonen, M. Niemela, S. Haffner, K. Pyorala, J. 
Tuomilehto and FINMONICA Myocardial Infarction Register Study Group, Impact of 
diabetes on mortality after the first myocardial infarction, Diabetes Care 21: 69–75, 1998. 
 
Ministerio de Salud Pu´blica, Direccio´n Nacional de Estadı´stica, Anuario Estadı´stico 1995, 
Habana, 1996. 
 
Modan M, Karp M, Bauman B, Gordon O, Danon YL, Laron Z: Mortality in Israeli Jewish 
patients with type 1 (insulin-dependent) diabetes mellitus diagnosed prior to 18 years of age: a 
population based study. Diabetologia 34:515–520, 1991 
 
Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. 
N Engl J Medi 1984; 311: 89–93 
 
Molitch ME, Rutledge B, Steffes M, Cleary P. Renal insufficiency in the absence of 
albuminuria among adults with type 1 diabetes in the Diabetes Control and Complications 
Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study. 
Diabetes 2006; 55:S6A 
 
  106
Morrison EY, Ragoobirsingh D, Thompson H, Fletcher C, Smith Richardson S, Mcfarlane S: 
Phaisc insulin-dependent diabetes mellitus: manifestations and cellular mechanisms. J Clin 
Endocrinol Metab; 80: 1996–2001, 1995. 
 
Moss SE, Klein BEK, Klein R: The 14-year incidence of lower-extremity amputations in a 
diabetic population: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes 
Care 22:951–959, 1999. 
 
Moss SE, Klein R, Klein BEK. Cause-specific mortality in a population-based study of 
diabetes. Am J Public Health 81:1158-1162, 1991 
 
National Diabetes Data Group: Absolute and relative mortality in IDDM. In Diabetes in 
America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. 
Washington, DC, U.S. Govt. Printing Office, 1995 (NIH publ. no. 95-1468), p. 223–224 
 
Nishimura R, LaPorte RE, Dorman JS, Tajima N, Becker DJ, Orchard TJ. Mortality trends in 
Type 1 diabetes: The Allegheny county (Pennsylvania) registry 1965–99. Diabetes Care, 
24:824–837, 2001. 
 
Nishimura R, Matsushima M, Tajima N, Agata T, Shimizu H, LaPorte RE: A major 
improvement in the prognosis of individuals with IDDM in the past 30 years in Japan. 
Diabetes Care 19 : 758–760, 1996. 
 
Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J: Declining incidence of severe 
retinopathy and persisting decrease of nephropathy in an unselected population of type 1 
diabetes: the Linkoping Diabetes Complications Study. Diabetologia 46:1266 –1272, 2004 
 
Norgaard K, Storm B, Graae M, Feldt Rasmussen B: Elevated albumin excretion and retinal 
changes in children with type 1 diabetes are related to long-term poor blood glucose control. 
Diabet Med 6:325–328, 1989 
 
Olson JC, Edmundowicz D, Becker DJ, Kuller LH, Orchard TJ: Coronary calcium in adults 
with type 1 diabetes. Diabetes 49:1571–1578, 2000 
 
Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ: Glycemia (or, in 
women, estimated glucose disposal rate) predict lower extremity arterial disease events in 
type 1 diabetes. Metabolism 51: 248 –254, 2002. 
 
Orchard TJ for the GCSP investigators: Validation of coronary heart disease mortality data: 
the Community Cardiovascular Surveillance Project Pilot Experience. Am Heart Assoc 
Cardiovasc Dis Epidemiol Newslett 157: 46, 1985 
 
Orchard TJ, Chang YF, Ferrell RE et al. Nephropathy in type 1 diabetes: A manifestation of 
insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh 
Epidemiology of Diabetes Complication Study. Kid Int 62: 963–970, 2002 
 
Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: 
Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of 
Diabetes Complications Study II. Diabetes 39: 1116-1124, 1990. 
 
  107
Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE, Kuller LH, Wolfson SK, 
Drash AL: Factors associated with avoidance of severe complications after 25 yr of IDDM. 
Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 13: 741-747, 
1990. 
 
Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, 
Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease 
in type 1 diabetes. Diabetes Care 26:1374–1379, 2003. 
 
Orchard TJ, Pambianco G, Wilson R, Zgibor J, Creola D. The Natural history of type 1 
diabetes (T1D) complications. Diabetes 51 (suppl. 2): A535, 2002 
 
Orchard TJ, Virella G, Forrest KYZ, Evans RW, Becker DJ, Lopes-Virella MF: Antibodies to 
oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study 
from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48:1454–1458, 
1999. 
 
Pajunen P, Taskinen M-R, Nieminen MS, Syva¨nne M: Angiographic severity and extent of 
coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol 86:1080–1085, 
2000 
 
Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ: The 30-year natural 
history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes 
Complications Study experience. Diabetes 55:1463–1469, 2006 
 
Panahloo A, Andres C & Mohamed-Ali V et al. The insertion allele of the ACE gene I/D 
polymorphism—A candidate gene for insulin resistance? Circulation 1995; 92: 3390−3393. 
 
Panzram G: Epidemiologic data on excess mortality and life expectancy in insulin-dependent 
diabetes mellitus. Crit Rev Exp Clin Endocrinol 82:93-100, 1984. 
 
Parfrey PS, Hutchinson TA, Harvey C, Guttmann RD. Transplantation versus dialysis in 
diabetic patients with renal failure. Am J Kidney Dis. 2:112-116, 1985. 
 
Patrick SL, Tajima N, LaPorte RE, Kitagawa T for the Diabetes Epidemiology Research 
International (DERI) Japan-U.S. Mortality Study Group (1992) A comparison of renal disease 
mortality among individuals with insulin-dependent diabetes mellitus (IDDM) in Japan and 
Allegheny County, PA, the United States. J Japan Diab Soc 35: 993–1000, 1992. 
 
Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, Schober E, 
Gyürüs E, Castell C, Urbonaité B, Rosenbauer J, Iotova V, Thorsson AV, Soltész G: Early 
mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood 
since 1989, Diabetologia 50:2439–2442, 2007. 
 
Podar T, Solntsev A, Reunanen A et al: Mortality in patients with childhood-onset type 1 
diabetes in Finland, Estonia, and Lithuania. Follow-up of nationwide cohorts. Diabetes Care 
23:290–294, 2000. 
 
Pollack AA, McGurl TJ, Macintyre N. Diabetes mellitus. Arch Intern Med 1967; 119: 161-
163. 
  108
 
Pollare T, Lithell H & Berne C. A comparison of the effects of hydrochlorothiazide and 
captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 
321: 868−873. 
 
Quattrin T, Waz WR, Duffy LC, Sheldon M W, Campos SP, Albini CH, Feld LG: 
Microalbuminuria in an adolescent cohort with insulin-dependent diabetes mellitus. Clin 
Pediatr (Phila) 34:12–17, 1995 
 
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction 
in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832-1839. 
 
Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126, 1999. 
 
Rossing P, Hougaard P, Borch Johnsen K, P a rving HH: Predictors of mortality in insulin 
dependent diabetes: 10 year observational follow up study. BMJ 313: 779–784, 1996 
 
Rudberg S, Ullman E, Dahlquist G: Relationship between early metabolic control and the 
development of microalbuminuria : a longitudinal study in children with type 1 (insulin-
dependent) diabetes mellitus. Diabetologia 36:1309–1314, 1993 
 
Salardi, S, Cacciari, E, Pascucci, MG, Giambiasi, E, Tacconi, M, Tazzari, R, Cicognani, A, 
Boriani, F, Puglioli, R, Mantovani, W: Microalbuminuria in diabetic children and adolescents: 
relationship with puberty and growth hormone. Acta Paediatr Scand 79:437-443, 1990 
 
Sartor G, Nyström L, Dahlquist G: The Swedish Childhood Diabetes Study: a seven-fold 
decrease in short-term mortality?Diabet Med 8:18–21, 1991. 
 
Schultz CJ, Konopelska-Bahu R. Dalton N at al. Microalbuminuria Prevalence Varies With 
Age, Sex, and Puberty in Children With Type 1 Diabetes Followed From Diagnosis in a 
Longitudinal Study. Diabetes Care 22:495–502, 1999 
 
Scibilia J, Finegold D, Dorman J, et al. Why do children with diabetes die? Acta 
Endocrinologica Suppl; 279:326-333, 1986. 
 
Segi M, Kurihara M: Trends in Cancer Mortality for selected sites in 24 countries, 1950–
1959,Department of Public Health, Tohoku University School of Medicine, Senday, Japan, 
1963, p. 2. 
 
Simpson AJ, Booth NA, Moore NR, Gray RS: Does chronic smoking influence fibrinolytic 
potential in type 1 diabetes mellitus? Diabet Med 15: 683-687, 1998. 
 
Singh TP, Groehn H, Kazmers A: Vascular function and carotid intimal-medial thickness in 
children with insulin-dependent diabetes mellitus. J AmColl Cardiol 41:661– 665, 2003. 
 
Smets YF, Westendorp RG, van der Pijl JW, et al : Effect of simultaneous pancreaskidney 
transplantation on mortality of patients with type-1 diabetes mellitus and endstage renal 
failure. Lancet. 353:1915-1919, 1999 
 
  109
Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ, Pittsburgh Epidemiology 
of Diabetes Complications S. Lipoprotein subclass measurements by nuclear magnetic 
resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. 
A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. 
Diabetologia 46: 674–682, 2003 
 
Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, 
Fuller JH, the EURODIAB Prospective Complications Study Group: Risk factors for 
coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective 
Complications Study. Diabetes Care 27:530–537, 2004. 
 
Stamler J, Vaccaro O, Neaton JD, Wentworth D and Multiple Risk Factor Intervention Trial 
Research Group, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men 
screened in the Multiple Risk Factor Intervention Trial, Diabetes Care 16 (1993), pp. 434–
444. 
 
Stuhldreher WL, Orchard TJ, Ellis D: The association of waist-hip ratio and risk factors for 
development of IDDM complications in an IDDM adult population. Diabetes Res Clin Pract 
1992; 17: 99-109. 
 
Sultz HA, Schlesinger ER, Mosher WE, Feldman JG: Long-term childhood illness. Pittsburgh, 
University of Pittsburgh Press, 1972:223-248. 
 
Takaro T, P. Peduzzi, K.M. Detre, H.N. Hultgren, M.L. Murphy, J. van der Bel-Kahn, J. 
Thomsen and W.R. Meadows, Survival in subgroups of patients with left main coronary 
artery disease Veterans Administration Cooperative Study of Surgery for Coronary Arterial 
Occlusive Disease, Circulation 66: 14–22, 1982. 
 
The Bypass Angioplasty Revascularisation Investigation (BARI) investigators. Seven-year 
outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and 
diabetic status. J Am Coll Cardiol 2000;35:1122–9. 
 
The Bypass Angioplasty Revascularization Investigation (BARI) investigators: Influence of 
diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA 
in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation. 
Circulation 96:1761-1769, 1997. 
 
The Bypass Angioplasty Revascularization Investigation (BARI) investigators, Comparison 
of coronary bypass surgery with angioplasty in patients with multivessel disease, N Engl J 
Med 335: 217–225, 1996. 
 
The Bypass Angioplasty Revascularization Investigation (BARI) investigators, The Final 10-
Year Follow-Up Results From the BARI Randomized Trial, Journal of the American College 
of Cardiology 49: 1600–1606, 2007. 
 
Thordarson H, Sovik O. Dead in bed syndrome in young diabetic patients in Norway. Diabet 
Med; 12:495-496, 1995. 
 
  110
Torffvit O, Lovestam-Adrian M, Agardh E, Agardh C-D: Nephropathy, but not retinopathy, is 
associated with the development of heart disease in type 1 diabetes: as 12-year observation 
study of 462 patients. Diabet Med 22:723–729, 2005. 
 
Tull ES, Barinas E, Pittsburgh DERI Mortality Study Group: A twofold excess mortality 
among black compared with white IDDM patients in Allegheny County, Pennsylvania. 
Diabetes Care 19:1344–1347, 1996 
 
Tuomilehto J, Borch-Johnsen K, Molarius A, Forse´n T, Rastenyte D, Sarti C, Reunanen A: 
Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and 
without diabetic nephropathy in Finland. Diabetologia 41:784 –790, 1998. 
 
Tsimikas S: Drug-eluting stents and late adverse clinical outcomes: lessons learned, lessons 
awaited. J Am Coll Cardiol 47: 2112–2115, 2006. 
 
United States Renal Data System (USRDS) Coordinating Center (2001), USRDS 2001 Annual 
Data Report. 
 
US Census Bureau, Statistic Abstract of the United States, 2000, p29.  
 
US Department of Health and Human Services, Vital Statistics of the United States 1992, vol. 
II – Mortality, Part A, Maryland, 1996, p. 8. 
 
Valsania P, Zarich SW, Kowalchuk GJ, Kosinski E, Warram JH, Krolewski AS: Severity of 
coronary artery disease in young patients with insulin-dependent diabetes mellitus. Am Heart 
J 122:695–700, 1991 
 
Veglio M, Giunti S, Stevens LK, Fuller JH, Perin PC, the EURODIAB IDDM Complications 
Study Group: Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with 
cardiac ischemia: the EURODIAB IDDM Complications Study Group. Diabetes Care 
25:702–707, 2002. 
 
Viberti GC, Hill RD, Jarrett RJ et al.: Microalbuminuria as a predictor of clinical nephropathy 
in insulin-dependent diabetes mellitus. Lanceti:1430–1432, 1982 
 
Wagener DK, Sacks JM, LaPorte RE, MacGregor JM: The Pittsburgh Study of Insulin-
dependent Diabetes Mellitus: risk for diabetes among relatives of IDDM. Diabetes 31:136 –
144, 1982 
 
Wang SL, Head J, Stevens L, Fuller JH, World Health Organization Multinational Study. 
Excess Mortality and Its Relation to Hypertension and Proteinuria in Diabetic Patients. 
Diabetes Care; 19(4): 305-312, 1996. 
 
Warner DP, McKinney PA, Law GR, Bodansky HJ: Mortality and diabetes from a population 
based register in Yorkshire 1978–93. Arch Dis Child 8:435– 438, 1998. 
 
Warram JH, Scott LJ, Hanna LS, Wantman M, Cohen SE, Laffel LM, et al. Progression of 
microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. 
Diabetes 2000; 49: 94–100 
 
  111
Watts GF, Harris R, Shaw KM: The determinants of early nephropathy in insulin dependent 
diabetes mellitus: a peospective study based on the urinary excretion of albumin. QJM 
79:365–378, 1991 
 
Wedel H, Nilsson PEW: High mortality in the Baltic states. SVEPET 4:3–4, 1992. 
 
Weintraub WS, Ghazzal ZM, Douglas JS, et al. Long-term clinical follow-up in patients with 
angiographic restudy after successful angioplasty. Circulation 1993;87:831– 40. 
 
West KM. Epidemiology of diabetes and its macrovascular complications. Diabetes Care; 
2:63-64, 1979. 
 
White P: Natural course and prognosis of juvenile diabetes. Diabetes 1956; 5: 445-450. 
 
WHO Multinational Project for Childhood Diabetes: WHO Diamond Project Group .Diabetes 
Care 13:1062–1068, 1990. 
 
Williams D, Erbey J, Becker D, Orchard TJ: Can clinical factors estimate insulin resistance in 
type 1 diabetes? Diabetes 49:626–632, 2000. 
 
Wolfe RA, Ashby VB, Milford EL, et al.: Comparison of mortality in all patients on dialysis, 
patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N 
Engl J Med. 341:1725-1730, 1999 
 
World Health Organization DiaMond Project Group: WHO Multinational Project for 
Childhood Diabetes. Diabetes Care 39:858-864, 1990 
 
Yip J, Matlock MB & Morocutti A et al. Insulin resistance in insulin-dependent diabetic 
patients with microalbuminuria. Lancet 1993; 342: 883−887. 
 
Yishak AA, Costacou T, Virella G at al. Novel predictors of overt nephropathy in subjects 
with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of 
Diabetes Complications cohort. Nephrol Dial Transplan. 2006; 21(1):93-100 
 
Yusuf S, D. Zucker, P. Peduzzi, L.D. Fisher, T. Takaro, J.W. Kennedy, K. Davis, T. Killip, E. 
Passamani and R. Norris et al., Effect of coronary artery bypass graft surgery on survival 
overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft 
Surgery Trialists Collaboration, Lancet 344: 563–570, 1994. 
 
  112
9. Acknowledgements 
 
The entire research work could not have been done without the kind contribution from and 
help of a number of great people, including professors, diabetes specialists, epidemiologists, 
nurses and assistants. 
First of all, I would like to thank my first mentors, Professor Gyula Tamás and Dr. Zsuzsa 
Kerényi for their kind willingness to open the gate for me not only toward the world of 
diabetes epidemiology and research but also clinical diabetology and practice. Without their 
active management I would not have been able to improve my skills in understanding the 
importance of numbers and rates in the field of modern clinical practice. 
I also would like to acknowledge my former mentor, Professor Trevor Orchard, one of the 
greatest teachers in diabetes epidemiology that he gave me the opportunity to work under his 
mentorship at the University of Pittsburgh, Department of Epidemiology where I started my 
training in Epidemiology as a young physician. He was always ready to help me in improving 
my research skills by providing resources for new study ideas, and he showed a lot of 
patience and understanding as well during my 2-year stay in the US. 
In regards to research projects I was involved in, I also thank Alberto Barcelo, Rimei 
Nishimura for their extensive advice; Melissa Hagan Hughes, Georgia Pambianco, Lesa 
Thomas (†), Nancy Silvers, Idamae Gower and Robb Wilson for their contribution in 
contacting patients and data management; and of course study participants and their families 
for their willing assistance during data collection and evaluation. Studies conducted in the US 
were partly supported by a grant from the Imperial Boshi Aiikkukai Foundation, National 
Institutes of Health Grant DK-34818 (Epidemiology of Diabetes Complications Study), and 
the American Diabetes Association Mentor-Based Fellowship Program. I also thank the DERI 
International Mortality Group, especially Drs. Naoko Tajima and Jakkoo Tuomilehto for their 
valuable contribution in the Mortality Classification Committee meetings. 
I would like to express my appreciation toward my current mentor, Professor Gyula Soltész, 
for involving my work into his doctoral program and for giving me the opportunity to take 
part in epidemiological research at the University of Pecs, Department of Pediatrics. I also 
want to thank him for his expertise and in particular for his kind understanding and patience 
during the years we worked together on this PhD thesis.  
Last but not least, I dedicate this work to my wife, Anita who has always provided me the 
right family background and tolerated many times my commitment toward diabetes research. 
  113
10. Appendices 
10.1. DERI Study complication survey 
 
Diabetes Update  
Date                 /                  /         Family ID                  Case ID 
Name  
Last                                 First                                        Maiden 
Please correct your name , address and phone number if the information below is 
wrong. 
Address                                                                
  
Phone  
Please answer the questions below and fill in the year and month of the first 
diagnosis where appropriate.  
1) Have you ever had Renal Dialysis? 
no              yes  ( start date: year                     / month                  )           
2) Have you received Renal Transplantation?  
no                 yes  (first surgery: year                 / month                  ) 
If yes, which one have you received? 
    renal only   both renal and pancreas         
3) Have you received Photocoagulation Therapy (laser treatment of the eyes)? 
no                 yes  (first therapy: year                 / month                  )           
4) Do you have history of Myocardial Infarction (Heart Attack)? 
no                 yes (first attack: year                     / month                  )   
5) Have you ever had Angioplasty (PTCA) ? 
no                 yes (first therapy: year                  / month                  ) 
6) Have you ever had Coronary Bypass Surgery? 
           no                 yes (first surgery: year                   / month                      ) 
7) Do you have history of Stroke? 
no                 yes (first stroke: year                     / month                  )           
8) Have you ever had an Amputation? 
           no                 yes  (first surgery: year                   / month                   /site:         ) 
9) Have you ever had an ilio femoral bypass surgery (bypass of the artery to the legs)?  
no                 yes (first surgery: year                   / month                  )  
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